Solid forms of (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione
Patent Information
- Application Number
- JP2023536058
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-04-26
- Filing Date
- 2021-12-13
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2041-12-13
Smart Images

Figure 2022128849000001 
Figure 2022128849000002 
Figure 2022128849000003
Abstract
Description
[Technical Field]
[0001] (Field of invention) In this specification, in particular, the solid form of the present invention, pharmaceutical compositions containing the same, methods for producing the same, and the use of the solid form or compositions for the prevention and / or treatment of inflammatory conditions, muscle diseases, fibrous diseases, viral infections, and / or diseases involving cartilage degradation and / or disruption of cartilage homeostasis are provided. [Background technology]
[0002] (Background of the invention) ADAMTS-5 was identified in 1999 (Abbaszade et al., 1999). In 2005, two independent groups identified ADAMTS-5 as the major aggrecanase in mouse cartilage (Glasson et al., 2005; Stanton et al., 2005). Aggrecan proteolysis by ADAMTS-5 occurs at various sites; however, cleavage at the Glu373-Ala374 bond (aggrecan IGD) appears to be of high importance in the pathogenesis of osteoarthritis and inflammatory arthritis because loss of integrity at this bond leads to the loss of the entire aggrecan molecule, which is highly detrimental to cartilage integrity and function (Little et al., 2007).
[0003] Studies in genetically modified mouse models (GeMMs) have shown that disruption of ADAMTS-5 is protective against cartilage damage and aggrecan loss following osteoarthritis induction due to surgical instability of the medial meniscus (DMM) (Glasson et al., 2005). Furthermore, in DMM models, ADAMTS-5 knockout mice showed reduced subchondral bone changes (Botter et al., 2009) and did not develop osteoarthritis-associated mechanical allodynia (Malfait et al., 2010). In addition to preclinical evidence, clinical evidence also indicates the importance of ADAMTS-5 as a target for osteoarthritis and the interest therein. Recently, studies using antibodies targeting ADAMTS-5 (Chiusaroli et al., 2013) have been reported. ELISAs have been developed that enable the measurement of aggrecanase-derived cartilage neoepitope levels in synovial fluid and blood from rodents to humans. This method revealed increased levels of ADAMTS-5-induced neoepitope in rat joints where cartilage degradation was induced by meniscal tears and in the joints of osteoarthritis patients, thereby providing further translational evidence regarding the importance of this protease in the development of osteoarthritis (Chockalingam et al., 2011; Larsson et al., 2014).
[0004] These findings provide strong evidence regarding the central role of ADAMTS-5 in the pathology of osteoarthritis as a key target, and ADAMTS-5 inhibitors that can reach sufficient levels in articular cartilage are expected to exert a protective effect on the cartilage of patients with osteoarthritis.
[0005] More recently, the role of ADAMTS5 has been confirmed in further diseases, including muscle diseases (Addinsall et al., 2020), hepatic fibrosis (Bauters et al., 2018, 2016), renal fibrosis (Collins and Wann, 2020; Taylor et al., 2020), pulmonary fibrosis such as IPF (Pardo et al., 2008), and / or viral infections such as influenza (McMahon et al., 2016).
[0006] In this context, a new drug is under development, in particular the compound (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazine-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione or GLPG1972 or S201086 or aldumast: [ka] However, it is still under development.
[0007] (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione of formula (I) is disclosed in WO2016 / 102347, and is an ADAMTS-5 inhibitor which may also be useful in the prevention and / or treatment of inflammatory conditions, muscle diseases, fibrous diseases, viral infections, and / or diseases involving cartilage degradation and / or disruption of cartilage homeostasis, particularly osteoarthritis.
[0008] A key characteristic of various physiologically active substances (e.g., pharmaceuticals, medicines, and biocides, commonly referred to as drugs, but not limited to these) is their "bioavailability," or the concentration of activity in a form that can be absorbed and utilized by target organs or organisms. Often, bioavailability is related to the solubility of a drug in water, which can depend on many parameters, including acid-basicity and / or polymorphism.
[0009] Drugs in the free base form can be poorly soluble in water, but can conveniently utilize the presence of acidic moieties (e.g., carboxylic acid, phenol, sulfonic acid) or basic moieties (e.g., amino group, basic nitrogen center) to form salts of the drug. The resulting ionic compounds exhibit much higher water solubility due to their ionic nature and reduced dissolution energy, and thus can improve bioavailability. A guideline of 50 μg / mL for water solubility has been provided by Lipinski et al. (Lipinski et al., 2001).
[0010] Numerous salt formers are available, and the choice of salt must be carefully designed. The aim of salt selection is to identify the best salt form suitable for development, mainly based on four major criteria: water solubility at various pHs, high crystallinity, low hygroscopicity, and optimal chemical stability (Stahl et al., 2011).
[0011] Polymorphism is a property of the solid state of some molecules (and molecular complexes), where a single molecule gives rise to diverse distinct crystal structures with different physical properties that can be characterized by determining melting point, thermal behavior using thermogravimetric analysis (TGA) or differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), infrared absorption fingerprint, and / or solid ( 13 C) NMR spectra.
[0012] If a preferred solid form of a drug or its salt, such as a crystalline or polymorphic form, is identifiable, further investigation can be conducted, both qualitatively and quantitatively, to identify alternative solid forms. The availability of such solid forms is highly unpredictable and may require a combination of intuition, careful empirical design, tenacity, and serendipity. In addition to the challenges associated with finding one or more distinct solid forms, the properties of any such forms discovered must be carefully evaluated to determine whether one or more of them are actually suitable for drug development. In practice, in the first aspect, among physical and mechanical properties, the crystallinity of the drug in particular can affect solubility, dissolution rate, flowability, hardness, compressibility, and / or melting point. In the second aspect, crystalline forms may have advantages over amorphous forms; for example, purification to the high purity required by most regulatory authorities may be more efficient, and therefore potentially less expensive in the case of crystalline forms than in the case of amorphous solids. In addition, handling of the crystalline form may be improved compared to the amorphous form, which may be oily or sticky, and in practice, drying of crystalline materials with well-defined drying or desolvation temperatures may be easier to control than in the case of amorphous solids, which may have a higher affinity for organic solvents and fluctuating drying temperatures. Finally, downstream processing of crystalline drugs may, in some cases, allow for improved process control. In a third aspect, physical and chemical stability and / or shelf life may be improved in the crystalline form compared to the amorphous form.
[0013] Further pharmacokinetic and pharmacodynamic properties of a drug may be related to a specific solid or crystalline structural form, and it is of paramount importance to manufacture and maintain that form from manufacture to administration to the patient. Therefore, the availability of salt and / or crystalline forms superior to amorphous materials is highly desirable (Hilfiker et al., 2006).
[0014] For example, there is a consistent demand for drug compounds with improved stability, solubility, shelf life, and in vivo pharmacology, which continues to create a need for new or purer solid forms of existing drug molecules. [Overview of the project]
[0015] (Summary of the invention) This specification provides, in particular, the solid form of the present invention and pharmaceutical compositions containing the same, as well as methods for producing the same, and the use of the solid form or compositions for the prevention and / or treatment of inflammatory conditions, muscle diseases, fibrous diseases, viral infections, and / or diseases involving cartilage degradation and / or disruption of cartilage homeostasis, in particular osteoarthritis.
[0016] Therefore, in the first embodiment, in particular, the solid form of the present invention having formula (I) - hereinafter referred to as compound 1: (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazine-1-yl]-3-oxo-propyl]imidazolidined-2,4-dione of formula (I): [ka] It will be provided.
[0017] In a first embodiment, the solid form of the present invention is crystalline. In a more specific embodiment, the solid form of the present invention is anhydrous. In another embodiment, the solid form is hydrated. In yet another embodiment, the solid form is solvated.
[0018] In another embodiment, the solid form of the present invention is amorphous. In another embodiment, the solid form is solvated. In another embodiment, the solid form is not solvated.
[0019] In particular, a solid form of the present invention is provided for use in the prevention and / or treatment of inflammatory conditions, muscle diseases, fibrous diseases, viral infections, and / or diseases involving cartilage degradation and / or disruption of cartilage homeostasis.
[0020] Furthermore, it has been unexpectedly shown that the solid form of the present invention exhibits improved exposure compared to other solid forms of compound 1.
[0021] In a further embodiment, a pharmaceutical composition comprising the solid form of the present invention and a pharmaceutical carrier, excipient, or diluent is provided. In a particular embodiment, the pharmaceutical composition may further comprise a further therapeutic active ingredient suitable for use in combination with the solid form of the present invention. In a more particular embodiment, the further therapeutic active ingredient is an agent for the prevention and / or treatment of inflammatory conditions, muscle diseases, fibrous diseases, viral infections, and / or diseases involving cartilage degradation and / or disruption of cartilage homeostasis.
[0022] Furthermore, the solid forms of the present invention useful in pharmaceutical compositions and therapeutic methods provided herein are pharmaceutically acceptable at the time of preparation and use.
[0023] In a further embodiment, a method is provided for treating a mammal, particularly a human, suffering from a disease selected from those listed herein, in particular inflammatory conditions, muscle diseases, fibrous diseases, viral infections, and / or diseases involving cartilage degradation and / or disruption of cartilage homeostasis, the method comprising administering an effective amount of the pharmaceutical composition or solid form of the present invention as described herein.
[0024] In particular, this specification also provides pharmaceutical compositions comprising the solid form of the present invention and suitable pharmaceutical carriers, excipients, or diluents for use in pharmaceuticals. In certain embodiments, the pharmaceutical compositions are for use in the prevention and / or treatment of inflammatory conditions, muscle diseases, fibrous diseases, viral infections, and / or diseases involving cartilage degradation and / or disruption of cartilage homeostasis.
[0025] In additional embodiments, methods for synthesizing the solid forms of the present invention are provided herein, in particular, using representative synthesis protocols and routes disclosed below herein. Other purposes and advantages will become apparent to those skilled in the art from consideration of the following detailed description. [Brief explanation of the drawing]
[0026] (Drawing description) [Figure 1] Figure 1: Powder X-ray diffraction profile of crystal morphology I [Figure 2] Figure 2: Powder X-ray diffraction profile of crystal morphology II [Figure 3] Figure 3: DSC profile of crystal morphology I [Figure 4] Figure 4: DSC profile of crystal morphology II [Figure 5] Figure 5: TGA profile of crystal morphology I [Figure 6] Figure 6: TGA profile of crystal morphology II [Figure 7] Figure 7: IR spectrum of crystal morphology I [Figure 8] Figure 8: IR spectrum of crystal morphology II [Figure 9] Figure 9: 13C solid-state NMR spectrum of crystal morphology I [Figure 10] Figure 10: 13C solid-state NMR spectrum of crystal morphology II [Figure 11] Figure 11: 15N solid-state NMR spectrum of crystal morphology I [Figure 12] Figure 12: 15N solid-state NMR spectrum of crystal morphology II [Figure 13] Figure 13: DVS profile of crystal morphology I [Figure 14] Figure 14: DVS profile of crystal morphology II [Figure 15] Figure 15: Powder X-ray diffraction profile of crystal morphology III [Figure 16] Figure 16: DSC profile of crystal morphology III [Figure 17] Figure 17: TGA profile of crystal morphology III [Figure 18] Figure 18: Powder X-ray diffraction profile of amorphous compound 1 [Figure 19] Figure 19: TGA profile of amorphous compound 1 [Figure 20] Figure 20: DSC profile of amorphous compound 1 [Figure 21] Figure 21: Urinary protein / creatinine ratios for compound 1 (group A, black circles), vehicle (group B, black squares), lisinopril (group C, upward-pointing black triangles), and sham (group D, downward-pointing black triangles). [Figure 22] Figure 22: Muscle grip strength (g / g) corrected for body weight - y-axis - Before treatment, during treatment, and at the end of treatment in a Duchenne dystrophy model (mouse MDX assay) - x-axis - For each group: vehicle (black circle), compound 1 (black square), prednisolone (upward-pointing black triangle), and compound 1 + prednisolone (downward-pointing black triangle) [Figure 23] Figure 23: Post-treatment bone volume fraction (bone volume / tissue volume, %, y axis) for the vehicle group (A), compound 1 group (B), prednisolone group (C), and prednisolone + compound 1 combination (D) (x axis) in a Duchenne dystrophy model (mouse mdx assay). [Modes for carrying out the invention]
[0027] (Detailed description of the invention) (definition) The following terms are intended to have the meanings presented below and are useful in understanding the description and intended scope of the present invention.
[0028] When describing the present invention, which may encompass compounds, pharmaceutical compositions containing such compounds, and methods of using such compounds and compositions, the following terms, where present, have the following meanings unless otherwise specified. It should also be understood that, where used herein, any part defined below may be substituted with various substituents, and that each definition is intended to include such substituted parts within the range shown below. Unless otherwise specified, the term “substituted” shall be defined as shown below. It should also be understood that the terms “group” and “radical” may be considered interchangeable where used herein.
[0029] The articles “a” and “an” may be used herein to refer to one or more (i.e., at least one) of the grammatical objects of the articles. For example, “an analogue” means one analogue or more analogues.
[0030] "Acceptable as a medicine" means that it is approved or may be approved for use in animals, more specifically in humans, by a federal or state regulatory authority or a corresponding regulatory authority in a country other than the United States, or that it is listed in the United States Pharmacopeia or any other generally accepted pharmacopoeia.
[0031] "Pharmacovigilant salts" refer to salts of the compounds of the present invention that are pharmacovigilant and possess the desired pharmacological activity of the parent compound. Specifically, such salts are nontoxic and may be inorganic or organic acid addition salts and base addition salts. Specifically, such salts are: (1) formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid; or formed with acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbenzoic acid (2) Acid addition salts formed with organic acids such as cyclo[2.2.2]-octa-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfate, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic acid; or (2) salts formed when an acidic proton present in the parent compound is substituted with a metal ion, such as an alkali metal ion, an alkaline earth ion, or an aluminum ion; or when it coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, or N-methylglucamine. Salts further include, but only as examples, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, etc.; and, if the compound contains basic functionality, salts of non-toxic organic or inorganic acids such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate, etc. The term "pharmaceutically acceptable cation" refers to an acceptable cationic counterion of an acidic functional group. Examples of such cations include sodium, potassium, calcium, magnesium, ammonium, and tetraalkylammonium cations.
[0032] "Pharmacopoeia-acceptable vehicle" refers to a diluent, adjuvant, excipient, or carrier to which the compound of the present invention is administered.
[0033] The terms "inert solid diluent," "solid diluent," or "diluent" refer to a material used to produce a suitable dosage form, size, performance, and processability for tablets and / or capsules. Inert solid diluents are sometimes also referred to as fillers or filler materials. Specific examples of diluents include powdered cellulose, silicified microcrystalline cellulose acetate, compressible sugar, powdered sugar, corn starch and pregelatinized starch, dextrose, dextrin, glucose, erythritol, ethylcellulose, fructose, fumaric acid, glyceryl palmitostearate, inhaled lactose, isomalt, kaolin, lactitol, anhydrous lactose, lactose monohydrate, and corn starch, spray-dried monohydrate and microcrystalline cellulose, maltodextrin, maltose, mannitol, medium-chain triglycerides, microcrystalline cellulose, polydextrose, polymethacrylate, simethicone, sorbitol, pregelatinized starch, sterilizable corn, sucrose, sugar spheres, sulfobutyl ether, β-cyclodextrin, talc, tragacanth, trehalose, or xylitol. More specific examples of diluents include powdered cellulose, silicified microcrystalline cellulose acetate, compressible sugars, corn starch and pregelatinized starch, glucose, fructose, glyceryl palmitostearate, anhydrous, monohydrate and corn starch, spray-dried monohydrate and microcrystalline cellulose, maltodextrin, maltose, mannitol, medium-chain triglycerides, microcrystalline cellulose, polydextrose, sorbitol, starch, pregelatinized starch, sucrose, sugar globules, trehalose, or xylitol.
[0034] A "lubricant" refers to a material that prevents ingredients from clumping together and sticking to a tablet press or capsule filling machine. The lubricant also ensures that tablets are formed and ejected reliably, with sufficient friction between the low-level solid and the mold wall. Specific examples of lubricants include canola oil, hydrogenated castor oil, cottonseed oil, glyceryl behenate, glyceryl monostearate, glyceryl palmitostearate, magnesium stearate, medium-chain triglycerides, mineral oil, light mineral oil, octyldodecanol, poloxamer, polyethylene glycol, polyoxyethylene stearate, polyvinyl alcohol, starch, or hydrogenated vegetable oils. More specific examples of lubricants include magnesium stearate, glyceryl behenate, glyceryl monostearate, or hydrogenated vegetable oils.
[0035] A "disintegrant" refers to a material that dissolves when wet, causing the tablet to break apart in the digestive tract and release the active ingredient for absorption. This ensures that when the tablet comes into contact with water, it rapidly disintegrates into smaller fragments, facilitating dissolution. Specific examples of disintegrants include alginic acid, powdered cellulose, chitosan, colloidal silicon dioxide, corn starch and pregelatinized starch, crospovidone, glycine, guar gum, low-substituted hydroxypropyl cellulose, methylcellulose, microcrystalline cellulose, croscarmellose sodium, or povidone.
[0036] The term "coloring agent" refers to a chemical used to give color to a preparation. Specific examples of coloring agents include iron oxide or synthetic organic dyes (U.S. Food and Drug Administration, Code of Federal Regulations, Title 21 CFR Part 73, Subpart B).
[0037] The terms "plasticizing agent" or "plasticizer" refer to agents added to improve the flexibility of a film or coating. Specific examples of plasticizing agents include polyethylene glycol or propylene glycol.
[0038] The term "pigment" refers to an insoluble coloring agent.
[0039] The terms “film coating agent,” “coating agent,” or “coating material” refer to agents used to create a decorative or functional layer on the outer surface of a dosage form. Specific examples of film coating agents include glucose syrup, maltodextrin, alginate, or carrageenan.
[0040] A "flow accelerator" refers to a material used to promote the flow of powder by reducing friction and cohesive forces between particles. Because it does not have the ability to reduce friction on mold walls, it is used in combination with a lubricant. Specific examples of flow accelerators include powdered cellulose, colloidal silicon dioxide, hydrophobic colloidal silica, silicon dioxide, or talc. More specific examples of flow accelerators include colloidal silicon dioxide, hydrophobic colloidal silica, silicon dioxide, or talc.
[0041] "Flavoring agents" refer to materials that can be used to mask unpleasant-tasting active ingredients and improve a patient's tolerance for completing the course of drug therapy. Flavoring agents may be natural (e.g., fruit extracts) or artificial. Non-exclusive examples of flavoring agents include mint, cherry, anise, peach, apricot, licorice, raspberry, or vanilla.
[0042] A "prodrug" refers to a compound containing a derivative of the compound of the present invention that has a cleavable group and becomes a pharmaceutically active compound of the present invention in vivo by solvolysis or under physiological conditions. Examples of such compounds, but not limited to these, include choline ester derivatives and N-alkylmorpholine esters.
[0043] A “solvate” typically refers to a form of compound that has associated with a solvent through solvolysis. This physical association includes hydrogen bonding. Common solvents include water, ethanol, and acetic acid. The compounds of the present invention may be prepared, for example, in crystalline form and may be solvated or hydrated. Preferred solvates include pharmaceutically acceptable solvates such as hydrates, and further include both stoichiometric and non-stoichiometric solvates. In some cases, a solvate may be isolated, for example, if one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. “Solvates” encompass both solution phases and isolable solvates. Representative solvates include hydrates, ethanolates, and methanolates.
[0044] Where used herein, “solid form of the present invention” and equivalent expressions are intended to encompass amorphous or crystalline compounds of formula(s) described herein, including, where circumstances permit, pharmaceutically acceptable salts and solvates, e.g., hydrates, and solvates of such pharmaceutically acceptable salts. Similarly, references to intermediates, whether or not they themselves are claimed, are intended to encompass, where circumstances permit, their salts and solvates.
[0045] As used herein, the terms “polymorph” or “polymorphic form” refer to multiple crystalline forms of the same molecule. Different polymorphic forms of a molecule have different physical properties as a result of the arrangement or conformation of the molecule within the crystal lattice. Some of the different properties of crystals include melting temperature, heat of fusion, solubility, dissolution rate, and / or vibrational spectrum. The physical form of a particular compound is particularly important when the compound is used in a pharmaceutical formulation, because different solid forms of the compound result in different properties of the drug product.
[0046] Molecular polymorphisms can be obtained by many methods as described in this art, such as melt-recrystallization, melt-cooling, solvent-recrystallization, desolvation, rapid evaporation, rapid cooling, slow cooling, vapor diffusion, and sublimation. Techniques for characterizing polymorphisms include powder X-ray diffraction (XRPD), single-crystal X-ray diffraction (XRD), differential scanning calorimetry (DSC), vibrational spectroscopy (e.g., IR and Raman spectroscopy), solid-state nuclear magnetic resonance (ssNMR), hot-stage optical microscopy, scanning electron microscopy (SEM), electron beam crystal structure analysis and quantitative analysis, particle size analysis (PSA), surface area analysis, solubility tests, and dissolution tests.
[0047] The term "hydrate" refers to a chemical substance formed by the interaction of water with another compound.
[0048] As used herein, the term “dihydrate” means a hydrate containing two molecules of water per molecule of substrate.
[0049] As used herein, the term "crystalline" means a solid in which the constituent atoms, molecules, or ions are arranged in a three-dimensionally regular, orderly, repeating pattern.
[0050] This specification and the claims include lists of kinds using the phrases "selected from... and..." and "is... or...". Where used in this application, unless otherwise specified, these phrases are intended to include the group as a whole, or any single member thereof, or any subgroup thereof. The use of these phrases is solely for abbreviated purposes and is not intended to restrict the removal of individual elements or subgroups as needed.
[0051] Where a scope is referred to herein, the reference to the scope should be considered to represent each member of that scope.
[0052] "Subject" includes human beings. The terms "human being," "patient," and "subject" are used interchangeably in this specification.
[0053] "Effective dose" means the amount of the compound of the present invention that, when administered to a subject to treat a disease, is sufficient to produce a cure for such disease. The "effective dose" can vary depending on the compound, the disease and its severity, as well as the age, weight, etc., of the subject to be treated.
[0054] "Prevention" or "prevention" means reducing the risk of developing or acquiring a disease or disability (i.e., preventing the development of at least one clinical symptom of a disease before the disease develops in a person who may be exposed to a disease-causing substance or who may be predisposed to the disease).
[0055] The term "prophylaxis" is related to "prevention" and refers to measures or treatments whose purpose is to prevent a disease rather than to treat or cure it. Non-exclusive examples of preventive measures include the administration of vaccines; for example, the administration of low molecular weight heparin to hospitalized patients at risk of thrombosis due to immobility; and the administration of antimalarial drugs such as chloroquine prior to visiting geographical areas where malaria is endemic or where the risk of contracting malaria is high.
[0056] In one embodiment, “treating” or “treatment” of any disease or disorder means improving the disease or disorder (i.e., stopping the disease or reducing at least one sign, extent, or severity of its clinical symptoms). In another embodiment, “treating” or “treatment” means improving at least one physical parameter that is not recognizable by the subject. In yet another embodiment, “treating” or “treatment” means modifying the disease or disorder physically (e.g., stabilizing recognizable symptoms) or physiologically (e.g., stabilizing physical parameters), or both. In yet another embodiment, “treating” or “treatment” relates to slowing the progression of the disease.
[0057] As used herein, the term “inflammatory disease” means a group of conditions including rheumatoid arthritis, osteoarthritis, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, allergic respiratory diseases (e.g., asthma, rhinitis), chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), endotoxin-driven conditions (e.g., complications after bypass surgery or, for example, chronic endotoxin states contributing to chronic heart failure), and cartilage-related diseases such as joint diseases. In particular, the term means rheumatoid arthritis, osteoarthritis, allergic respiratory diseases (e.g., asthma), chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease. More specifically, the term means rheumatoid arthritis and osteoarthritis (OA). Most specifically, the term means osteoarthritis (OA).
[0058] As used herein, the term “muscle disease” means a group of diseases in which abnormal genes (mutations) interfere with the production of proteins necessary for forming healthy muscles, resulting in progressive weakness and loss of muscle mass. In particular, the term means muscular dystrophy. More specifically, the term means Duchenne muscular dystrophy, Becker muscular dystrophy, myotonic dystrophy, facioscapulohumeral dystrophy, congenital dystrophy, and / or limb-girdle dystrophy. Most specifically, the term means Duchenne muscular dystrophy.
[0059] As used herein, the term “fibrous disease” means a disease characterized by excessive scarring due to the overproduction, deposition, and contraction of the extracellular matrix, and associated with the abnormal accumulation of cells and / or fibronectin and / or collagen, and / or increased fibroblast recruitment. In particular, the term means fibrosis of individual organs or tissues such as, for example, the heart, kidneys, liver, joints, lungs, pleural tissue, peritoneal tissue, skin, cornea, retina, musculoskeletal system, and gastrointestinal tract. In particular, the term fibrotic disease encompasses a wide range of conditions including pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis (IPF), progressive fibrotic form of interstitial lung disease (PF-ILD), progressive nodular fibrosis (PMF), and / or cystic fibrosis (CF)), other diffuse parenchymal lung diseases of various etiologies including iatrogenic drug-induced fibrosis, occupational-induced fibrosis, and / or environmental-induced fibrosis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonitis), collagen vascular diseases, alveolar proteinosis, Langerhans cell granulomatosis, lymphangioleiomyomatosis, genetic disorders (Hermanskie-Pudlak syndrome, tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease); radiation-induced fibrosis; chronic obstructive pulmonary disease (COPD); scleroderma; bleomycin-induced pulmonary fibrosis; chronic asthma; silicosis; asbestos-induced pulmonary fibrosis; and acute asthma. Respiratory distress syndrome (ARDS); renal fibrosis; polycystic kidney disease (PKD), autosomal dominant polycystic kidney disease (ADPKD), tubulointerstitial fibrosis; glomerulonephritis; focal segmental glomerulosclerosis; IgA nephropathy, membranous nephropathy; hypertension; Alport syndrome; intestinal fibrosis; hepatic fibrosis; cirrhosis; alcohol-induced hepatic fibrosis; toxin / drug-induced hepatic fibrosis; hemochromatosis; non-alcoholic steatohepatitis (NAS) H); Bile duct injury; Primary biliary cirrhosis; Infection-induced hepatic fibrosis; Viral-induced hepatic fibrosis; and autoimmune hepatitis; Corneal scarring; Hypertrophic scarring; Dupuytren's disease, keloids, cutaneous fibrosis; Scleroderma; Systemic sclerosis, spinal cord injury / fibrosis; Myelofibrosis; Vascular restenosis; Atherosclerosis; Arteriosclerosis; Wegener's granulomatosis; Peyronie's disease, or chronic lymphocytic. More specifically, the term means idiopathic pulmonary fibrosis (IPF), progressive fibrotic form of interstitial lung disease (PF-ILD), IgA nephropathy, membranous nephropathy, focal segmental glomerulosclerosis, autosomal dominant polycystic kidney disease (ADPKD), and / or non-alcoholic steatohepatitis (NASH).
[0060] As used herein, the term “viral infection” means an infection in the body caused by a virus. In particular, the term means influenza (the flu).
[0061] As used herein, the term “diseases involving cartilage breakdown and / or disruption of cartilage homeostasis” includes conditions such as osteoarthritis, psoriatic arthritis, juvenile rheumatoid arthritis, gouty arthritis, septic or infectious arthritis, reactive arthritis, reflex sympathetic dystrophy, painful osteodystrophy, achondroplasia, Paget’s disease, Tietze syndrome or costochondritis, fibromyalgia, osteochondritis, neurogenic or neuropathic arthritis, arthropathy, sarcoidosis, amylosis, hydarthrosis, periodic disease, rheumatoid spondylitis, endemic forms of arthritis such as endemic osteoarthritis, Muserenian disease and Handigodú disease; degeneration caused by fibromyalgia, systemic lupus erythematosus, scleroderma, and ankylosing spondylitis. More specifically, the term means osteoarthritis (OA).
[0062] "The compound(s) of the present invention" and equivalent expressions mean to encompass the compound(s) of formula(s) described herein, and, where contextually permissible, this expression means to encompass pharmaceutically acceptable salts and solvates, e.g., hydrates, and solvates of pharmaceutically acceptable salts. Similarly, references to intermediates mean to encompass their salts and solvates, where contextually permissible, whether or not they themselves are claimed.
[0063] In this specification, for example, but not limited to, C 1-8 When ranges such as alkyl are mentioned, the reference to the range should be considered an indication of each member of that range.
[0064] Other derivatives of the compounds of the present invention are active in both their acid and acid derivative forms, however the acid-sensitive forms often offer advantages such as solubility, tissue compatibility, or delayed release in mammals (Bundgard, H., 1985). Prodrugs include acid derivatives well known to experts in the field, such as esters prepared by the reaction of a hydrophilic acid with a suitable alcohol, or amides, acid anhydrides, or mixed anhydrides prepared by the reaction of a hydrophilic compound with a substituted or unsubstituted amine. Simple aliphatic or aromatic esters, amides, and anhydrides derived from the acidic groups attached to the compounds of the present invention are particularly useful prodrugs. In some cases, it is desirable to prepare double ester-type prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkyl esters. Certain such prodrugs are C of the compounds of the present invention. 1-8 Alkyl, C 2-8 Alkenyl, optionally substituted C 6-10 Aryl, and (C 6-10 Ariel)-(C 1-4 It is an alkyl ester.
[0065] This disclosure includes all isotopic forms of the compounds of the invention provided herein, whether (i) all atoms of a given atomic number are in the form having the mass number (or mixture of mass numbers) that is dominant in nature (referred to herein as the "natural isotopic form"), or (ii) one or more atoms are replaced with atoms having the same atomic number but a mass number different from that of the atoms that are dominant in nature (referred to herein as the "non-natural variant isotopic form"). It is understood that an atom may occur naturally as a mixture of multiple mass numbers. The term "non-natural variant isotopic form" also includes embodiments where the ratio of atoms of a given atomic number having a mass number that is less common in nature (referred to herein as "uncommon isotopes") is increased to a level of, for example, >20%, >50%, >75%, >90%, >95%, or >99% of the number of atoms of that atomic number, compared to what occurs in nature (the latter embodiments are referred to as "isotope-enriched variant forms"). The term "non-natural variant isotopic form" also includes embodiments where the ratio of uncommon isotopes is decreased compared to what occurs in nature. Isotopic forms can include radioactive forms (i.e., those incorporating a radioactive isotope) and non-radioactive forms. Radioactive forms are typically isotope-enriched variant forms.
[0066] Thus, non-natural variant isotopic forms of a compound have, in one or more atoms, one or more deuteriums ( 2 H or D), carbon-11 ( 11 C), carbon-13 ( 13 C), carbon-14 ( 14 C), nitrogen-13 ( 13 N), nitrogen-15 ( 15 N), oxygen-15 ( 15 O), oxygen-17 ( 17 O), oxygen-18 ( 18 O), phosphorus-32 ( 32 P), sulfur-35 ( 35 S), chlorine-36 ( 36 Cl), chlorine-37 ( 37 Cl), fluorine-18 ( 18 F), iodine-123 (123 I) Iodine-125 125 It may contain artificial or uncommon isotopes such as (I), or it may contain an increased ratio of such isotope in one or more atoms compared to the ratio that is dominant in nature.
[0067] Non-natural variant isotopic forms containing radioactive isotopes can be used, for example, in tissue distribution studies of drugs and / or substrates. Radioactive isotope tritium, i.e., 3 H, and carbon-14, i.e. 14 C, considering that its incorporation is easy and detection means are readily available, is particularly useful for this purpose. Deuterium, i.e., 2 Non-natural variant isotopic forms incorporating H or D may offer certain therapeutic benefits, such as increased metabolic stability, an increased in vivo half-life, or a reduced required dose, and may therefore be preferable in certain situations. Furthermore, 11 C, 18 F, 15 O, and 13 Non-natural variant isotopic forms incorporating positron-emitting isotopes such as 13N may be prepared, which would be useful in positron emission topography (PET) studies to investigate substrate receptor occupancy.
[0068] It should also be understood that compounds having the same molecular formula but differing in the properties or arrangement of their atomic bonds, or in the spatial arrangement of those atoms, are called "isomers." Isomers with differing spatial arrangements of their atoms are called "stereoisomers."
[0069] Stereoisomers that are not mirror images of each other are called "diastereomers," while stereoisomers that are mirror images of each other but cannot be superimposed are called "enantiomers." If a compound has a chiral center, for example, if it is bonded to four different groups, a set of enantiomers is possible. Enantiomers can be characterized by the absolute configuration of their chiral center and described by the Kahn-Prelogue R- and S-order rules, or by the way the molecule rotates its plane of polarization and is named and characterized as dextrorotatory or levorotatory (i.e., (+) or (-)-isomers, respectively). Chiral compounds can exist as individual enantiomers or as mixtures thereof. A mixture containing enantiomers in equal proportions is called a "racemic mixture."
[0070] A "tautomer" refers to a compound that is an interchangeable form of a particular compound structure and differs in terms of the rearrangement of hydrogen atoms and electrons. Thus, the two structures can be in equilibrium via the transfer of π electrons and atoms (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either an acid or a base. Another example of tautomerism is the ac and nitro forms of phenylnitromethane, which are similarly formed by treatment with either an acid or a base.
[0071] Tautomeristic forms may be related to achieving optimal chemical reactivity and biological activity of the target compound.
[0072] The compounds of the present invention may have one or more chiral centers; therefore, such compounds can be prepared as individual (R)- or (S)-stereoisomers, or as mixtures thereof.
[0073] Unless otherwise indicated, the descriptions or nomenclasms of specific compounds in this specification and the claims are intended to include both individual enantiomers and mixtures thereof, whether racemic or not. Methods for determining stereochemistry and separating stereoisomers are well known in the art.
[0074] It will be recognized that the compounds of the present invention may be metabolized to produce biologically active metabolites.
[0075] (This invention) This specification provides, in particular, a solid form of (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidined-2,4-dione of formula (I), as well as pharmaceutical compositions containing the same and methods for producing the same, and the use of the solid form or compositions for the prevention and / or treatment of inflammatory conditions, muscle diseases, fibrous diseases, viral infections, and / or diseases involving cartilage degradation and / or disruption of cartilage homeostasis, in particular osteoarthritis. [ka]
[0076] In one embodiment, the solid form of the present invention is amorphous.
[0077] In one embodiment, the solid form of the present invention is a crystalline form.
[0078] In one embodiment, the solid form of the present invention is a solvate. In a particular embodiment, the solid form of the present invention is a hydrate or a dihydrate. In a more particular embodiment, the solid form of the present invention is a dihydrate.
[0079] In one embodiment, the solid form of the present invention is not solvated. In a particular embodiment, the solid form of the present invention is anhydrous.
[0080] In one embodiment, the solid form of the present invention is the dihydrate form (Form I) of (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione. In the most specific embodiment, the solid form of the present invention is the crystalline dihydrate form (Form I) of (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione.
[0081] In another embodiment, the solid form of the present invention is the anhydrous form (Form II) of (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazine-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione. In the most specific embodiment, the solid form of the present invention is the crystalline anhydrous form (Form II) of (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazine-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione.
[0082] (Amorphous form) In one embodiment, the solid form of the present invention is amorphous. In one embodiment, the solid form of the present invention is characterized by a powder X-ray diffraction pattern substantially consistent with that of Figure 18.
[0083] In one embodiment, the solid form of the present invention is amorphous and further features a DSC curve substantially consistent with that of Figure 20.
[0084] In one embodiment, the solid form of the present invention is amorphous and features a powder X-ray diffraction pattern substantially consistent with Figure 18 and a DSC curve substantially consistent with Figure 20.
[0085] (polymorphic form I) Provided herein, in particular, is the dihydrate solid form of (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidin-2,4-dione. In another embodiment, the solid form of the present invention is crystalline (Form I). In yet another embodiment, the solid form of the present invention is crystalline (Form I) and may be characterized by one or more of the parameters described in further detail below.
[0086] In one embodiment, the solid form of the present invention is polymorph I and may be characterized by a powder X-ray diffraction pattern having one or more peaks at the following positions: 6.2, 12.5, 14.1, 14.6, 15.6, 15.7, 17.8, 18.0, 18.8, 19.1, 19.7, 20.8, 21.4, 22.4, 25.2, 26.4, 28.9, or 29.0 ± 0.2° 2θ.
[0087] In the most specific embodiment, the solid form of the present invention is polymorph I and may be characterized by a powder X-ray diffraction pattern having one or more peaks at the following positions: 6.2, 12.5, 14.1, 14.6, 15.6, 15.7, 17.8, 18.0, 18.8, 19.1, 19.7, 20.8, 21.4, 22.4, 25.2, 26.4, 28.9, or 29.0 ± 0.2° 2θ; and a powder X-ray diffraction pattern substantially as shown in Figure 1.
[0088] In certain embodiments, the solid form of the present invention is polymorph I and may be characterized by a powder X-ray diffraction pattern having at least 1, 5, 10, 15 or more peaks at the following positions: 6.2, 12.5, 14.1, 14.6, 15.6, 15.7, 17.8, 18.0, 18.8, 19.1, 19.7, 20.8, 21.4, 22.4, 25.2, 26.4, 28.9, or 29.0 ± 0.2° 2θ.
[0089] In certain embodiments, the solid form of the present invention may be polymorph I and characterized by a powder X-ray diffraction pattern having peaks at the following positions: 6.2, 12.5, 15.7, 19.1, 25.2, and 26.4 ± 0.2° 2θ.
[0090] In a particular embodiment, the solid form of the present invention may be polymorph I and characterized by a powder X-ray diffraction pattern having peaks at the following positions: 6.2, 12.5, 14.1, 15.7, 19.1, 21.4, 22.4, 25.2, and 26.4 ± 0.2° 2θ.
[0091] In a particular embodiment, the solid form of the present invention is polymorph I and may be characterized by a powder X-ray diffraction pattern having peaks at the following positions: 6.2, 12.5, 14.1, 14.6, 15.6, 15.7, 17.8, 18.0, 18.8, 19.1, 19.7, 20.8, 21.4, 22.4, 25.2, 26.4, 28.9, and 29.0 ± 0.2° 2θ.
[0092] In one embodiment, the solid form of the present invention is polymorph I and may be characterized by a powder X-ray diffraction pattern substantially as shown in Figure 1. In a particular embodiment, the solid form of the present invention is polymorph I and further characterized by the DSC profile of Figure 3. In a particular embodiment, the solid form of the present invention is polymorph I and further characterized by the TGA profile of Figure 5.
[0093] (polymorphic form II) Provided herein, in particular, is an anhydrous solid form of (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidin-2,4-dione. In another embodiment, the solid form of the present invention is crystalline (Form II). In yet another embodiment, the solid form of the present invention is crystalline (Form II) and may be characterized by one or more of the parameters described in further detail below.
[0094] In one embodiment, the solid form of the present invention is polymorphic form II and may be characterized by a powder X-ray diffraction pattern having one or more peaks at the following positions: 8.5, 10.3, 12.6, 13.2, 13.6, 14.7, 15.3, 15.7, 16.7, 18.3, 18.6, 20.3, 20.8, 22.9, 24.5, 27.2, or 30.4 ± 0.2° 2θ.
[0095] In one embodiment, the solid form of the present invention is polymorphic form II and may be characterized by a powder X-ray diffraction pattern having at least 1, 5, 10, 15 or more peaks at the following positions: 8.5, 10.3, 12.6, 13.2, 13.6, 14.7, 15.3, 15.7, 16.7, 18.3, 18.6, 20.3, 20.8, 22.9, 24.5, 27.2, or 30.4 ± 0.2° 2θ.
[0096] In one embodiment, the solid form of the present invention is polymorphic form II and may be characterized by a powder X-ray diffraction pattern having peaks at the following positions: 10.3, 15.3, 15.7, 16.7, and 18.6 ± 0.2° 2θ.
[0097] In one embodiment, the solid form of the present invention is polymorphic form II and may be characterized by a powder X-ray diffraction pattern having peaks at the following positions: 10.3, 15.3, 15.7, 16.7, 18.6, 24.5, and 30.4 ± 0.2° 2θ.
[0098] In one embodiment, the solid form of the present invention is polymorphic form II and may be characterized by a powder X-ray diffraction pattern having peaks at the following positions: 8.5, 10.3, 12.6, 13.2, 13.6, 14.7, 15.3, 15.7, 16.7, 18.3, 18.6, 20.3, 20.8, 22.9, 24.5, 27.2, and 30.4, ±0.2° 2θ.
[0099] In one embodiment, the solid form of the present invention is polymorph II and may be characterized by a powder X-ray diffraction pattern substantially as shown in Figure 2. In a particular embodiment, the solid form of the present invention is polymorph II and further characterized by the DSC profile of Figure 4. In a more particular embodiment, the solid form of the present invention is polymorph II and further characterized by the TGA profile of Figure 6.
[0100] (polymorphic form III) Provided herein, in particular, is the solid form of (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidin-2,4-dione. In another embodiment, the solid form of the present invention is crystalline (Form III). In yet another embodiment, the solid form of the present invention is crystalline (Form III) and may be characterized by one or more of the parameters described in further detail below.
[0101] In one embodiment, the solid form of the present invention is polymorphic form III and may be characterized by a powder X-ray diffraction pattern having one or more peaks at the following positions: 9.0, 11.0, 11.4, 14.2, 15.0, 16.4, 16.6, 17.5, 18.1, 18.6, 18.8, 19.3, 20.0, 20.5, 21.7, 22.4, 23.4, 23.8, 26.2, 26.6, or 27.8 ± 0.2° 2θ.
[0102] In certain embodiments, the solid form of the present invention is polymorphic form III and may be characterized by a powder X-ray diffraction pattern having at least 1, 5, 10, 15 or more peaks at the following positions: 9.0, 11.0, 11.4, 14.2, 15.0, 16.4, 16.6, 17.5, 18.1, 18.6, 18.8, 19.3, 20.0, 20.5, 21.7, 22.4, 23.4, 23.8, 26.2, 26.6, or 27.8 ± 0.2° 2θ.
[0103] In certain embodiments, the solid form of the present invention may be polymorphic form III and characterized by a powder X-ray diffraction pattern having peaks at the following positions: 11.0, 16.6, 17.5, 18.8, 20.5, and 22.4 ± 0.2° 2θ.
[0104] In a particular embodiment, the solid form of the present invention is polymorphic form III and may be characterized by a powder X-ray diffraction pattern having peaks at the following positions: 9.0, 11.0, 14.2, 16.4, 16.6, 17.5, 18.6, 18.8, 20.5, 22.4, 23.4, and 26.2, ±0.2° 2θ.
[0105] In a particular embodiment, the solid form of the present invention is polymorphic form III and may be characterized by a powder X-ray diffraction pattern having peaks at the following positions: 9.0, 11.0, 11.4, 14.2, 15.0, 16.4, 16.6, 17.5, 18.1, 18.6, 18.8, 19.3, 20.0, 20.5, 21.7, 22.4, 23.4, 23.8, 26.2, 26.6, and 27.8 ± 0.2° 2θ.
[0106] In one embodiment, the solid form of the present invention may be polymorphic form III and characterized by a powder X-ray diffraction pattern substantially as shown in Figure 15. In a particular embodiment, the solid form of the present invention is polymorphic form III and further characterized by the DSC profile of Figure 16. In a more particular embodiment, the solid form of the present invention is polymorphic form III and further characterized by the TGA profile of Figure 17.
[0107] (Pharmaceutical composition) In some embodiments, the solid forms disclosed herein may be contained in solid dosage forms such as tablets. For example, in some embodiments, the solid forms disclosed herein may be provided in tablets in amounts ranging from 50 mg to 1000 mg. In some embodiments, tablets containing polymorph I in amounts from 50 mg to 1000 mg are provided. In some embodiments, tablets containing polymorph II in amounts from 50 mg to 1000 mg are provided. In some embodiments, tablets containing polymorph III in amounts from 50 mg to 1000 mg are provided. In some embodiments, tablets containing amorphous forms in amounts from 50 mg to 1000 mg are provided.
[0108] In one embodiment, a pharmaceutical composition comprising, in particular, the solid form of the present invention and an inert solid diluent is provided herein. In a particular embodiment, a pharmaceutical composition comprising, in particular, 29-31 wt% of polymorph I and 42-43 wt% of an inert solid diluent is provided herein. In a particular embodiment, the solid form of the present invention is polymorph I or polymorph II. In another particular embodiment, the inert solid diluent is lactose monohydrate.
[0109] In one embodiment, a pharmaceutical composition comprising, in particular, a solid form of the present invention, a first inert solid diluent, and a second inert solid diluent is provided herein. In a particular embodiment, a pharmaceutical composition comprising, in particular, 29-31 wt% of polymorph I, 42-43 wt% of the first inert solid diluent, and 19.5-20.5 wt% of the second inert diluent is provided herein. In a particular embodiment, the solid form of the present invention is polymorph I or polymorph II. In a more particular embodiment, the first inert solid diluent is lactose monohydrate. In yet another more particular embodiment, the first inert solid diluent is corn starch.
[0110] In one embodiment, a pharmaceutical composition comprising, in particular, a solid form of the present invention, a first inert solid diluent, and a second inert solid diluent is provided herein. In a particular embodiment, a pharmaceutical composition comprising, in particular, 29-31 wt% of polymorph I, 42-43 wt% of a first inert solid diluent, 19.5-20.5 wt% of a second inert diluent, and 6.5-7.5 wt% of a disintegrant is provided herein. In a particular embodiment, the solid form of the present invention is polymorph I or polymorph II. In a more particular embodiment, the first inert solid diluent is lactose monohydrate. In yet another more particular embodiment, the first inert solid diluent is corn starch. In yet yet another more particular embodiment, the disintegrant is povidone.
[0111] In one embodiment, a pharmaceutical composition comprising, in particular, a solid form of the present invention, a first inert solid diluent, and a second inert solid diluent is provided herein. In a particular embodiment, a pharmaceutical composition comprising, in particular, 29-31 wt% of polymorph I, 42-43 wt% of a first inert solid diluent, 19.5-20.5 wt% of a second inert diluent, 6.5-7.5 wt% of a disintegrant, and 0.15-0.25 wt% of a flow enhancer is provided herein. In a particular embodiment, the solid form of the present invention is polymorph I or polymorph II. In a more particular embodiment, the first inert solid diluent is lactose monohydrate. In another more particular embodiment, the first inert solid diluent is corn starch. In yet another more particular embodiment, the disintegrant is povidone. In yet another more particular embodiment, the flow enhancer is colloidal silicon dioxide.
[0112] In a particular embodiment, as described herein, in particular, by weight: 1) Solid form of the present invention in 29-31 wt% 2) 42-43 wt% lactose monohydrate 3) 19.5-20.5 wt% corn starch 4) 6.5-7.5 wt% povidone 5) 0.15-0.25 wt% colloidal silicon dioxide 6) 0.4-0.6 wt% magnesium stearate A pharmaceutical composition containing the following is provided.
[0113] In a particular embodiment, as described herein, in particular, by weight: 1) The solid form of the present invention at approximately 30 wt% 2) Approximately 42.3 wt% lactose monohydrate 3) Approximately 20 wt% corn starch 4) Approximately 7 wt% povidone 5) Approximately 0.2 wt% colloidal silicon dioxide 6) Approximately 0.5 wt% magnesium stearate A pharmaceutical composition containing the following is provided.
[0114] In a particular embodiment, as described herein, in particular, by weight: 1) Polymorph II of 29-31 wt% 2) 42-43 wt% lactose monohydrate 3) 19.5-20.5 wt% corn starch 4) 6.5-7.5 wt% povidone 5) 0.15-0.25 wt% colloidal silicon dioxide 6) 0.4-0.6 wt% magnesium stearate A pharmaceutical composition containing the following is provided.
[0115] In a particular embodiment, as described herein, in particular, by weight: 1) Polymorph II, approximately 30 wt% 2) Approximately 42.3 wt% lactose monohydrate 3) Approximately 20 wt% corn starch 4) Approximately 7 wt% povidone 5) Approximately 0.2 wt% colloidal silicon dioxide 6) Approximately 0.5 wt% magnesium stearate A pharmaceutical composition containing the following is provided.
[0116] In one embodiment, a pharmaceutical composition comprising, in particular, the solid form of the present invention and an inert solid diluent is provided herein. In a particular embodiment, a pharmaceutical composition comprising, in particular, 49-51 wt% of polymorph I and 22-23 wt% of an inert solid diluent is provided herein. In a particular embodiment, the solid form of the present invention is polymorph I or polymorph II. In another particular embodiment, the inert solid diluent is lactose monohydrate.
[0117] In one embodiment, a pharmaceutical composition comprising, in particular, a solid form of the present invention, a first inert solid diluent, and a second inert solid diluent is provided herein. In a particular embodiment, a pharmaceutical composition comprising, in particular, 49-51 wt% of polymorph I, 22-23 wt% of a first inert solid diluent, and 19.5-20.5 wt% of a second inert diluent is provided herein. In a particular embodiment, the solid form of the present invention is polymorph I or polymorph II. In a more particular embodiment, the first inert solid diluent is lactose monohydrate. In yet another more particular embodiment, the first inert solid diluent is corn starch.
[0118] In one embodiment, a pharmaceutical composition comprising, in particular, a solid form of the present invention, a first inert solid diluent, and a second inert solid diluent is provided herein. In a particular embodiment, a pharmaceutical composition comprising, in particular, 49-51 wt% of polymorph I, 22-23 wt% of a first inert solid diluent, 19.5-20.5 wt% of a second inert diluent, and 6.5-7.5 wt% of a disintegrant is provided herein. In a particular embodiment, the solid form of the present invention is polymorph I or polymorph II. In a more particular embodiment, the first inert solid diluent is lactose monohydrate. In yet another more particular embodiment, the first inert solid diluent is corn starch. In yet yet another more particular embodiment, the disintegrant is povidone.
[0119] In one embodiment, a pharmaceutical composition comprising, in particular, a solid form of the present invention, a first inert solid diluent, and a second inert solid diluent is provided herein. In a particular embodiment, a pharmaceutical composition comprising, in particular, 49-51 wt% of polymorph I, 22-23 wt% of a first inert solid diluent, 19.5-20.5 wt% of a second inert diluent, 6.5-7.5 wt% of a disintegrant, and 0.15-0.25 wt% of a flow enhancer is provided herein. In a particular embodiment, the solid form of the present invention is polymorph I or polymorph II. In a more particular embodiment, the first inert solid diluent is lactose monohydrate. In yet another more particular embodiment, the first inert solid diluent is corn starch. In yet yet another more particular embodiment, the disintegrant is povidone. In yet yet another more particular embodiment, the flow enhancer is colloidal silicon dioxide.
[0120] In a particular embodiment, as described herein, in particular, by weight: 1) Solid form of the present invention at 49-51 wt% 2) 22-23 wt% lactose monohydrate (diluent) 3) 19.5-20.5 wt% corn starch (diluent) 4) 6.5-7.5 wt% povidone (disintegrant) 5) 0.15-0.25 wt% colloidal silicon dioxide (flow enhancer) 6) 0.4-0.6 wt% magnesium stearate (lubricant) A pharmaceutical composition containing the following is provided.
[0121] In a particular embodiment, as described herein, in particular, by weight: 1) The solid form of the present invention at approximately 50 wt% 2) Approximately 22.3 wt% lactose monohydrate 3) Approximately 20 wt% corn starch 4) Approximately 7 wt% povidone 5) Approximately 0.2 wt% colloidal silicon dioxide 6) Approximately 0.5 wt% magnesium stearate A pharmaceutical composition containing the following is provided.
[0122] In a particular embodiment, as described herein, in particular, by weight: 1) Polymorph II of 49-51 wt% 2) 22-23 wt% lactose monohydrate (diluent) 3) 19.5-20.5 wt% corn starch (diluent) 4) 6.5-7.5 wt% povidone (disintegrant) 5) 0.15-0.25 wt% colloidal silicon dioxide (flow enhancer) 6) 0.4-0.6 wt% magnesium stearate (lubricant) A pharmaceutical composition containing the following is provided.
[0123] In a particular embodiment, as described herein, in particular, by weight: 1) Polymorph II, approximately 50 wt% 2) Approximately 22.3 wt% lactose monohydrate 3) Approximately 20 wt% corn starch 4) Approximately 7 wt% povidone 5) Approximately 0.2 wt% colloidal silicon dioxide 6) Approximately 0.5 wt% magnesium stearate A pharmaceutical composition containing the following is provided.
[0124] When used as a pharmaceutical, the compounds of the present invention are usually administered in the form of pharmaceutical compositions. Such compositions can be prepared in ways well known in the pharmaceutical field and may contain at least one active compound of the present invention according to Formula I. Typically, the compounds of the present invention are administered in amounts effective for pharmaceutical use. The amount of the compound of the present invention actually administered is usually determined by a physician, taking into account the condition to be treated, the chosen route of administration, the actual compound of the present invention administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and other relevant circumstances.
[0125] The pharmaceutical compositions of the present invention can be administered by various routes, including orally, rectally, transdermally, subcutaneously, intra-articularly, intravenously, intramuscularly, and intranasally. Depending on the intended delivery route, the compounds of the present invention are preferably formulated as injectable or oral compositions, or as ointments, lotions, or patches for all transdermal administration.
[0126] Compositions for oral administration may take the form of a bulk liquid solution or suspension, or a bulk powder. However, more commonly, the composition is provided in unit dosage forms to facilitate precise dosing. The term "unit dosage form" means a physically distinct unit suitable as a unit dose for human subjects and other mammals, each unit containing a predetermined amount of active material calculated to produce a desired therapeutic effect, in association with a suitable pharmaceutical excipient, vehicle, or carrier. Typical unit dosage forms include pre-filled and pre-measured ampoules or syringes for liquid compositions, or, in the case of solid compositions, pills, tablets, capsules, etc. In such compositions, the compound of the present invention according to Formula I is usually present in smaller amounts (about 0.1 to about 50 wt%, or preferably about 1 to about 40 wt%), with the remainder being various vehicles or carriers and processing aids that help form the desired dosage form.
[0127] Liquid forms suitable for oral administration may include suitable aqueous or non-aqueous vehicles containing buffers, suspending agents and dispersants, colorants, flavorings, etc. Solid forms may include, for example, the following components: binders, e.g., microcrystalline cellulose, tragacanth gum, or gelatin; excipients, e.g., starch or lactose; disintegrants, e.g., alginic acid, Primogel, or corn starch; lubricants, e.g., magnesium stearate; flow enhancers, e.g., colloidal silicon dioxide; sweeteners, e.g., sucrose or saccharin; or flavorings, e.g., peppermint or orange flavoring, or compounds of the present invention having similar properties.
[0128] The injectable compositions are typically based on sterile saline or phosphate-buffered saline or other injectable carriers known in the art. As described above, the active compound of the present invention according to formula I in such compositions is usually a smaller component, often about 0.05 to 10 wt%, with the remainder being the injectable carrier, etc.
[0129] Transdermal compositions are typically formulated as topical ointments or creams containing the active ingredient in an amount generally ranging from about 0.01 to about 20 wt%, preferably about 0.1 to about 20 wt%, preferably about 0.1 to about 10 wt%, and more preferably about 0.5 to about 15 wt%. When formulated as an ointment, the active ingredient is typically combined with either a paraffinic ointment base or a water-miscible ointment base. Alternatively, the active ingredient can be formulated in a cream, for example, with an oil-in-water cream base. Such transdermal formulations are well known in the art and typically contain the active ingredient or additional components that enhance the skin penetration or stability of the formulation. All such known transdermal formulations and components are within the scope of the present invention.
[0130] The compounds of the present invention can also be administered via transdermal devices. Therefore, transdermal administration can be achieved using a reservoir-type, porous membrane-type, or solid matrix-type patch.
[0131] The above-mentioned components for orally administered, injectable, or topically administered compositions are representative only. Other materials and processing techniques are described in Part 8 of Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania, which are incorporated herein by reference.
[0132] The compounds of the present invention can also be administered in a sustained-release form or via a sustained-release drug delivery system. A typical description of sustained-release materials can be found in Remington's Pharmaceutical Sciences.
[0133] The following examples illustrate typical pharmaceutical compositions that can be prepared according to the present invention. However, the present invention is not limited to the following pharmaceutical compositions.
[0134] (Formulation 1 - Tablets) The compound of the present invention according to Formula I can be mixed as a dry powder with a dry gelatin binder in a weight ratio of approximately 1:2. A small amount of magnesium stearate can be added as a lubricant. The mixture can be formed into 240-270 mg tablets (75 mg of the active compound of the present invention according to Formula I per tablet) using a tablet press.
[0135] (Formulation 2 - Capsule) The compound of the present invention according to Formula I can be mixed with a starch diluent in a weight ratio of approximately 1:1 as a dry powder. The mixture can be filled into 250 mg capsules (125 mg of the active compound of the present invention according to Formula I per capsule).
[0136] (Formulation 3 - Liquid formulation) The compound of the present invention according to formula I (125 mg) can be mixed with sucrose (1.75 g) and xanthan gum (4 mg). The resulting mixture can be blended and passed through a No. 10 mesh US sieve, and then mixed with a pre-prepared aqueous solution of microcrystalline cellulose and sodium carboxymethylcellulose (11:89, 50 mg). Sodium benzoate (10 mg), fragrance, and colorant can be diluted with water and added while stirring. Then, sufficient water can be added while stirring. Further sufficient water can then be added to produce a total volume of 5 mL.
[0137] (Formulation 4 - Tablets) The compound of the present invention according to Formula I can be mixed as a dry powder with a dry gelatin binder in a weight ratio of approximately 1:2. A small amount of magnesium stearate can be added as a lubricant. The mixture can be formed into 450-900 mg tablets (150-300 mg of the active compound of the present invention according to Formula I) using a tablet press.
[0138] (Example - Tablets) Weigh out 50g of compound 1, 22.5g of lactose monohydrate, 23g of microcrystalline cellulose, 0.5g of colloidal silica anhydrous, and 3g of croscarmellose sodium, transfer them to a suitable container, and mix them.
[0139] The resulting powder is dry-granulated using roller compression. The granules are sieved through a 500 μm sieve, and magnesium stearate (0.5 g) is added and mixed.
[0140] Next, the final mixture is compressed into tablets using a tablet press with a force of ±20N.
[0141] (Formulation 5 - Injectable) The compound of the present invention according to Formula I can be dissolved or suspended in an aqueous injection medium of buffered sterile physiological saline to a concentration of approximately 5 mg / mL.
[0142] (Formulation 6 - Topical Agent) Stearyl alcohol (250 g) and white petrolatum (250 g) can be melted at approximately 75°C, after which a mixture of the compound of the present invention according to formula I (50 g), methylparaben (0.25 g), propylparaben (0.15 g), sodium lauryl sulfate (10 g), and propylene glycol (120 g) dissolved in water (approximately 370 g) can be added, and the resulting mixture can be stirred until it solidifies.
[0143] (Treatment methods) In one embodiment, the present invention provides compounds of the present invention, or pharmaceutical compositions comprising compounds of the present invention, for use in the prevention and / or treatment of inflammatory diseases. In particular, the term means rheumatoid arthritis, osteoarthritis, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, allergic respiratory diseases (e.g., asthma, rhinitis), chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), endotoxin-driven conditions (e.g., complications after bypass surgery or, for example, chronic endotoxin states contributing to chronic heart failure), and cartilage-related diseases such as diseases of the joints. More specifically, the term means rheumatoid arthritis, osteoarthritis, asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
[0144] In another embodiment, the present invention provides the use of the compounds of the present invention, or pharmaceutical compositions comprising the compounds of the present invention, in the production of pharmaceuticals for the prevention and / or treatment of inflammatory diseases. In particular, the terms mean rheumatoid arthritis, osteoarthritis, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, allergic airway diseases (e.g., asthma, rhinitis), chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), endotoxin-driven conditions (e.g., complications after bypass surgery or, for example, chronic endotoxin states contributing to chronic heart failure), and cartilage-related diseases such as diseases of the joints. More specifically, the terms mean rheumatoid arthritis, osteoarthritis, asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
[0145] In an additional method of therapeutic application, the present invention provides a method for the prevention and / or treatment of a mammal suffering from an inflammatory disease, comprising the administration of an effective amount of one or more compounds of the present invention or pharmaceutical compositions described herein for the treatment or prevention of the disease. In particular, the term means rheumatoid arthritis, osteoarthritis, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, allergic respiratory diseases (e.g., asthma, rhinitis), chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), endotoxin-driven conditions (e.g., complications after bypass surgery or, for example, chronic endotoxin states contributing to chronic heart failure), and cartilage-related diseases such as joint diseases. More specifically, the term means rheumatoid arthritis, osteoarthritis, asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
[0146] In one embodiment, the present invention provides a pharmaceutical composition comprising the compound of the present invention and another therapeutic agent. In a particular embodiment, the other therapeutic agent is a therapeutic agent for inflammatory diseases. In particular, the term means rheumatoid arthritis, osteoarthritis, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, allergic respiratory diseases (e.g., asthma, rhinitis), chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), endotoxin-driven conditions (e.g., complications after bypass surgery or, for example, chronic endotoxin states contributing to chronic heart failure), and cartilage-related diseases such as joint diseases. More specifically, the term means rheumatoid arthritis, osteoarthritis, asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
[0147] In one embodiment, the present invention provides compounds of the present invention, or pharmaceutical compositions comprising compounds of the present invention, for use in the prevention and / or treatment of muscle diseases. In particular, the term means muscular dystrophy. More specifically, the term means Duchenne muscular dystrophy, Becker muscular dystrophy, myotonic dystrophy, facioscapulohumeral dystrophy, congenital dystrophy, and / or limb-girdle dystrophy. Most specifically, the term means Duchenne muscular dystrophy.
[0148] In another embodiment, the present invention provides the use of the compounds of the present invention, or pharmaceutical compositions comprising the compounds of the present invention, in the production of pharmaceuticals for the prevention and / or treatment of muscle diseases. In particular, the term means muscular dystrophy. More specifically, the term means Duchenne muscular dystrophy, Becker muscular dystrophy, myotonic dystrophy, facioscapulohumeral dystrophy, congenital dystrophy, and / or limb-girdle dystrophy. Most specifically, the term means Duchenne muscular dystrophy.
[0149] In an additional method of treatment, the present invention provides a method for the prevention and / or treatment of a mammal suffering from a muscle disease, comprising the administration of an effective amount of one or more compounds of the present invention or pharmaceutical compositions described herein for the treatment or prevention of the disease. In particular, the term means muscular dystrophy. More specifically, the term means Duchenne muscular dystrophy, Becker muscular dystrophy, myotonic dystrophy, facioscapulohumeral dystrophy, congenital dystrophy, and / or limb-girdle dystrophy. Most specifically, the term means Duchenne muscular dystrophy.
[0150] In one embodiment, the present invention provides a pharmaceutical composition comprising the compound of the present invention and another therapeutic agent. In a particular embodiment, the other therapeutic agent is a therapeutic agent for muscle diseases. In particular, the term means muscular dystrophy. More specifically, the term means Duchenne muscular dystrophy, Becker muscular dystrophy, myotonic dystrophy, facioscapulohumeral dystrophy, congenital dystrophy, and / or limb-girdle dystrophy. Most specifically, the term means Duchenne muscular dystrophy.
[0151] In one embodiment, the present invention provides compounds of the present invention, or pharmaceutical compositions comprising compounds of the present invention, for use in the prevention and / or treatment of fibrotic diseases. In particular, the term refers to fibrosis of individual organs or tissues such as the heart, kidneys, liver, joints, lungs, pleural tissue, peritoneal tissue, skin, cornea, retina, musculoskeletal system, and digestive tract. In particular, the term fibrotic disease encompasses a wide range of conditions including pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis (IPF), progressive nodular fibrosis (PMF), and / or cystic fibrosis (CF)), other diffuse parenchymal lung diseases of various etiologies including iatrogenic drug-induced fibrosis, occupational-induced fibrosis, and / or environmental-induced fibrosis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonitis), collagen vascular diseases, alveolar proteinosis, Langerhans cell granulomatosis, lymphangioleiomyomatosis, genetic disorders (Hermanskie-Pudlak syndrome, tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease); radiation-induced fibrosis; chronic obstructive pulmonary disease (COPD); scleroderma; bleomycin-induced pulmonary fibrosis; chronic asthma; silicosis; asbestos-induced pulmonary fibrosis; and acute respiratory distress syndrome (ARD). S); Renal fibrosis; Polycystic disease (PKD), autosomal dominant polycystic kidney disease (ADPKD), tubulointerstitial fibrosis; Glomerulonephritis; Focal segmental glomerulosclerosis; IgA nephropathy, membranous nephropathy; Hypertension; Alport; Intestinal fibrosis; Hepatic fibrosis; Cirrhosis; Alcohol-induced hepatic fibrosis; Toxic / drug-induced hepatic fibrosis; Hemochromatosis; Non-alcoholic steatohepatitis (NASH); Bile duct injury; Primary biliary cirrhosis; Infection-induced hepatic fibrosis; Viral-induced hepatic fibrosis; and Autoimmune hepatitis; Corneal scarring; Hypertrophic scarring; Dupuytren's disease, keloids, dermatofibrosis; Scleroderma; Systemic sclerosis, spinal cord injury / fibrosis; Myelofibrosis; Vascular restenosis; Atherosclerosis; Arteriosclerosis; Wegener's granulomatosis; Peyronie's disease, or chronic lymphocytic. More specifically, the term idiopathic pulmonary fibrosis (IPF) means IgA nephropathy, membranous nephropathy, focal segmental glomerulosclerosis, autosomal dominant polycystic kidney disease (ADPKD), and / or non-alcoholic steatohepatitis (NASH). Most specifically, the term idiopathic pulmonary fibrosis (IPF) means IgA nephropathy, autosomal dominant polycystic kidney disease (ADPKD), and / or non-alcoholic steatohepatitis (NASH).
[0152] In another embodiment, the present invention provides the use of the compounds of the present invention, or pharmaceutical compositions comprising the compounds of the present invention, in the production of pharmaceuticals for the prevention and / or treatment of fibrotic diseases. In particular, the terms refer to fibrosis of individual organs or tissues such as the heart, kidneys, liver, joints, lungs, pleural tissue, peritoneal tissue, skin, cornea, retina, musculoskeletal system, and digestive tract. In particular, the term fibrotic disease encompasses a wide range of conditions including pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis (IPF), progressive nodular fibrosis (PMF), and / or cystic fibrosis (CF)), other diffuse parenchymal lung diseases of various etiologies including iatrogenic drug-induced fibrosis, occupational-induced fibrosis, and / or environmental-induced fibrosis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonitis), collagen vascular diseases, alveolar proteinosis, Langerhans cell granulomatosis, lymphangioleiomyomatosis, genetic disorders (Hermanskie-Pudlak syndrome, tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease); radiation-induced fibrosis; chronic obstructive pulmonary disease (COPD); scleroderma; bleomycin-induced pulmonary fibrosis; chronic asthma; silicosis; asbestos-induced pulmonary fibrosis; and acute respiratory distress syndrome (ARD). S); Renal fibrosis; Polycystic disease (PKD), autosomal dominant polycystic kidney disease (ADPKD), tubulointerstitial fibrosis; Glomerulonephritis; Focal segmental glomerulosclerosis; IgA nephropathy, membranous nephropathy; Hypertension; Alport; Intestinal fibrosis; Hepatic fibrosis; Cirrhosis; Alcohol-induced hepatic fibrosis; Toxic / drug-induced hepatic fibrosis; Hemochromatosis; Non-alcoholic steatohepatitis (NASH); Bile duct injury; Primary biliary cirrhosis; Infection-induced hepatic fibrosis; Viral-induced hepatic fibrosis; and Autoimmune hepatitis; Corneal scarring; Hypertrophic scarring; Dupuytren's disease, keloids, dermatofibrosis; Scleroderma; Systemic sclerosis, spinal cord injury / fibrosis; Myelofibrosis; Vascular restenosis; Atherosclerosis; Arteriosclerosis; Wegener's granulomatosis; Peyronie's disease, or chronic lymphocytic. More specifically, the term idiopathic pulmonary fibrosis (IPF) means IgA nephropathy, membranous nephropathy, focal segmental glomerulosclerosis, autosomal dominant polycystic kidney disease (ADPKD), and / or non-alcoholic steatohepatitis (NASH). Most specifically, the term idiopathic pulmonary fibrosis (IPF) means IgA nephropathy, autosomal dominant polycystic kidney disease (ADPKD), and / or non-alcoholic steatohepatitis (NASH).
[0153] In an additional therapeutic method, the present invention provides a method for the prevention and / or treatment of a mammal suffering from a fibrous disease, comprising the administration of an effective amount of one or more of the compounds of the present invention or pharmaceutical compositions described herein for the treatment or prevention of the disease. In particular, the term means fibrosis of individual organs or tissues such as the heart, kidneys, liver, joints, lungs, pleural tissue, peritoneal tissue, skin, cornea, retina, musculoskeletal system, and gastrointestinal tract. In particular, the term fibrotic disease encompasses a wide range of conditions including pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis (IPF), progressive nodular fibrosis (PMF), and / or cystic fibrosis (CF)), other diffuse parenchymal lung diseases of various etiologies including iatrogenic drug-induced fibrosis, occupational-induced fibrosis, and / or environmental-induced fibrosis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonitis), collagen vascular diseases, alveolar proteinosis, Langerhans cell granulomatosis, lymphangioleiomyomatosis, genetic disorders (Hermanskie-Pudlak syndrome, tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease); radiation-induced fibrosis; chronic obstructive pulmonary disease (COPD); scleroderma; bleomycin-induced pulmonary fibrosis; chronic asthma; silicosis; asbestos-induced pulmonary fibrosis; and acute respiratory distress syndrome (ARD). S); Renal fibrosis; Polycystic disease (PKD), autosomal dominant polycystic kidney disease (ADPKD), tubulointerstitial fibrosis; Glomerulonephritis; Focal segmental glomerulosclerosis; IgA nephropathy, membranous nephropathy; Hypertension; Alport; Intestinal fibrosis; Hepatic fibrosis; Cirrhosis; Alcohol-induced hepatic fibrosis; Toxic / drug-induced hepatic fibrosis; Hemochromatosis; Non-alcoholic steatohepatitis (NASH); Bile duct injury; Primary biliary cirrhosis; Infection-induced hepatic fibrosis; Viral-induced hepatic fibrosis; and Autoimmune hepatitis; Corneal scarring; Hypertrophic scarring; Dupuytren's disease, keloids, dermatofibrosis; Scleroderma; Systemic sclerosis, spinal cord injury / fibrosis; Myelofibrosis; Vascular restenosis; Atherosclerosis; Arteriosclerosis; Wegener's granulomatosis; Peyronie's disease, or chronic lymphocytic. More specifically, the term idiopathic pulmonary fibrosis (IPF) refers to IgA nephropathy, membranous nephropathy, focal segmental glomerulosclerosis, autosomal dominant polycystic kidney disease (ADPKD), and / or non-alcoholic steatohepatitis (NASH).Most specifically, the term idiopathic pulmonary fibrosis (IPF) refers to IgA nephropathy, autosomal dominant polycystic kidney disease (ADPKD), and / or non-alcoholic steatohepatitis (NASH).
[0154] In one embodiment, the present invention provides a pharmaceutical composition comprising the compound of the present invention and another therapeutic agent. In a particular embodiment, the other therapeutic agent is a therapeutic agent for fibrotic diseases. In particular, the term means fibrosis of individual organs or tissues such as the heart, kidneys, liver, joints, lungs, pleural tissue, peritoneal tissue, skin, cornea, retina, musculoskeletal system, and gastrointestinal tract. In particular, the term fibrotic disease encompasses a wide range of conditions including pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis (IPF), progressive nodular fibrosis (PMF), and / or cystic fibrosis (CF)), other diffuse parenchymal lung diseases of various etiologies including iatrogenic drug-induced fibrosis, occupational-induced fibrosis, and / or environmental-induced fibrosis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonitis), collagen vascular diseases, alveolar proteinosis, Langerhans cell granulomatosis, lymphangioleiomyomatosis, genetic disorders (Hermanskie-Pudlak syndrome, tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease); radiation-induced fibrosis; chronic obstructive pulmonary disease (COPD); scleroderma; bleomycin-induced pulmonary fibrosis; chronic asthma; silicosis; asbestos-induced pulmonary fibrosis; and acute respiratory distress syndrome (ARD). S); Renal fibrosis; Polycystic disease (PKD), autosomal dominant polycystic kidney disease (ADPKD), tubulointerstitial fibrosis; Glomerulonephritis; Focal segmental glomerulosclerosis; IgA nephropathy, membranous nephropathy; Hypertension; Alport; Intestinal fibrosis; Hepatic fibrosis; Cirrhosis; Alcohol-induced hepatic fibrosis; Toxic / drug-induced hepatic fibrosis; Hemochromatosis; Non-alcoholic steatohepatitis (NASH); Bile duct injury; Primary biliary cirrhosis; Infection-induced hepatic fibrosis; Viral-induced hepatic fibrosis; and Autoimmune hepatitis; Corneal scarring; Hypertrophic scarring; Dupuytren's disease, keloids, dermatofibrosis; Scleroderma; Systemic sclerosis, spinal cord injury / fibrosis; Myelofibrosis; Vascular restenosis; Atherosclerosis; Arteriosclerosis; Wegener's granulomatosis; Peyronie's disease, or chronic lymphocytic. More specifically, the term idiopathic pulmonary fibrosis (IPF) means IgA nephropathy, membranous nephropathy, focal segmental glomerulosclerosis, autosomal dominant polycystic kidney disease (ADPKD), and / or non-alcoholic steatohepatitis (NASH). Most specifically, the term idiopathic pulmonary fibrosis (IPF) means IgA nephropathy, autosomal dominant polycystic kidney disease (ADPKD), and / or non-alcoholic steatohepatitis (NASH).
[0155] In one embodiment, the present invention provides a compound of the present invention, or a pharmaceutical composition comprising a compound of the present invention, for use in the prevention and / or treatment of viral infections. In particular, the terms mean influenza or flu.
[0156] In another embodiment, the present invention provides the use of the compounds of the present invention, or pharmaceutical compositions containing the compounds of the present invention, in the production of pharmaceuticals for the prevention and / or treatment of viral infections. In particular, the terms mean influenza or flu.
[0157] In addition to a therapeutic method, the present invention provides a method for the prevention and / or treatment of a mammal suffering from a viral infection, comprising administering an effective amount of one or more of the compounds of the present invention or pharmaceutical compositions described herein for the treatment or prevention of the disease.
[0158] In one embodiment, the present invention provides a pharmaceutical composition comprising the compound of the present invention and another therapeutic agent. In a particular embodiment, the other therapeutic agent is a therapeutic agent for viral infections.
[0159] In certain embodiments, the present invention provides compounds of the present invention, or pharmaceutical compositions comprising compounds of the present invention, for use in the prevention and / or treatment of diseases involving cartilage degradation and / or disruption of cartilage homeostasis. In certain embodiments, diseases involving cartilage degradation and / or disruption of cartilage homeostasis are selected from osteoarthritis, psoriatic arthritis, juvenile rheumatoid arthritis, gouty arthritis, septic or infectious arthritis, reactive arthritis, reflex sympathetic dystrophy, painful osteodystrophy, achondroplasia, Paget's disease, Tietze syndrome or costochondritis, fibromyalgia, osteochondritis, neurogenic or neuropathic arthritis, arthropathy, sarcoidosis, amylosis, hydarthrosis, periodic diseases, rheumatoid spondylitis, endemic forms of arthritis such as endemic osteoarthritis, Museren's disease and Handigodú's disease; degeneration caused by fibromyalgia, systemic lupus erythematosus, scleroderma, and ankylosing spondylitis. More specifically, the disease involving the breakdown of cartilage and / or disruption of cartilage homeostasis is osteoarthritis (OA).
[0160] In another embodiment, the present invention provides the use of the compounds of the present invention, or pharmaceutical compositions containing the compounds of the present invention, in the production of pharmaceuticals for the prevention and / or treatment of diseases involving cartilage degradation and / or disruption of cartilage homeostasis. In certain embodiments, diseases involving the breakdown of cartilage and / or disruption of cartilage homeostasis are selected from osteoarthritis, psoriatic arthritis, juvenile rheumatoid arthritis, gouty arthritis, septic or infectious arthritis, reactive arthritis, reflex sympathetic dystrophy, painful osteodystrophy, achondroplasia, Paget's disease, Tietze syndrome or costochondritis, fibromyalgia, osteochondritis, neurogenic or neuropathic arthritis, arthropathy, sarcoidosis, amylosis, hydarthrosis, periodic diseases, rheumatoid spondylitis, endemic forms of arthritis such as endemic osteoarthritis, Museren's disease and Handigodú disease; degeneration caused by fibromyalgia, systemic lupus erythematosus, scleroderma, and ankylosing spondylitis. More specifically, the disease involving the breakdown of cartilage and / or disruption of cartilage homeostasis is osteoarthritis (OA).
[0161] In an additional method of treatment, the present invention provides a method for the prevention and / or treatment of a mammal suffering from a disease involving cartilage degradation and / or disruption of cartilage homeostasis, comprising the administration of an effective amount of one or more of the compounds of the present invention or pharmaceutical compositions described herein for the treatment or prevention of the disease. A disease involving cartilage degradation and / or disruption of cartilage homeostasis. In certain embodiments, diseases involving the breakdown of cartilage and / or disruption of cartilage homeostasis are selected from osteoarthritis, psoriatic arthritis, juvenile rheumatoid arthritis, gouty arthritis, septic or infectious arthritis, reactive arthritis, reflex sympathetic dystrophy, painful osteodystrophy, achondroplasia, Paget's disease, Tietze syndrome or costochondritis, fibromyalgia, osteochondritis, neurogenic or neuropathic arthritis, arthropathy, sarcoidosis, amylosis, hydarthrosis, periodic diseases, rheumatoid spondylitis, endemic forms of arthritis such as endemic osteoarthritis, Museren's disease and Handigodú disease; degeneration caused by fibromyalgia, systemic lupus erythematosus, scleroderma, and ankylosing spondylitis. More specifically, the disease involving the breakdown of cartilage and / or disruption of cartilage homeostasis is osteoarthritis (OA).
[0162] In one embodiment, the present invention provides a pharmaceutical composition comprising the compound of the present invention and another therapeutic agent. In a particular embodiment, the other therapeutic agent is an agent for the treatment of a disease involving cartilage degradation and / or disruption of cartilage homeostasis, the method comprising administering an effective amount of one or more of the compound of the present invention or the pharmaceutical compositions described herein for the treatment or prevention of the disease. In certain embodiments, diseases involving the breakdown of cartilage and / or disruption of cartilage homeostasis are selected from osteoarthritis, psoriatic arthritis, juvenile rheumatoid arthritis, gouty arthritis, septic or infectious arthritis, reactive arthritis, reflex sympathetic dystrophy, painful osteodystrophy, achondroplasia, Paget's disease, Tietze syndrome or costochondritis, fibromyalgia, osteochondritis, neurogenic or neuropathic arthritis, arthropathy, sarcoidosis, amylosis, hydarthrosis, periodic diseases, rheumatoid spondylitis, endemic forms of arthritis such as endemic osteoarthritis, Museren's disease and Handigodú disease; degeneration caused by fibromyalgia, systemic lupus erythematosus, scleroderma, and ankylosing spondylitis. More specifically, the disease involving the breakdown of cartilage and / or disruption of cartilage homeostasis is osteoarthritis (OA).
[0163] For the prevention and / or treatment of long-term conditions such as degenerative states, therapeutic regimens are usually administered over several months or years, and therefore orally for the convenience and tolerability of the patient. Typical regimens for oral administration include 1 to 4 doses per day (1 to 4), particularly 1 to 3 doses per day (1 to 3), typically 1 to 2 doses per day (1 to 2), and most typically 1 dose per day (1). Alternatively, for long-acting drugs, typical regimens for oral administration include once every two weeks, once per week, and once daily. Specifically, dosing regimens may be every 1 to 14 days, more specifically every 1 to 10 days, even more specifically every 1 to 7 days, and most specifically every 1 to 3 days.
[0164] Using these dosing patterns, each dose provides approximately 1 to 1000 mg of the compound of the present invention, but specific doses provide approximately 10 to 500 mg each, and in particular, approximately 30 to 250 mg.
[0165] Transdermal doses are typically selected to provide blood levels similar to or lower than those achieved using injectable doses.
[0166] The injectable dose levels are all in the range of approximately 0.1 mg / kg / hour to at least 10 mg / kg / hour, over a period of approximately 1 to 120 hours, and especially between 24 and 96 hours. To achieve an appropriate steady-state level, a preloading bolus of approximately 0.1 mg / kg to 10 mg / kg or more may be administered. The maximum total dose is not expected to exceed approximately 1 g / day for human patients weighing 40-80 kg.
[0167] When used to prevent the onset of a disease, the compounds of the present invention would typically be administered to patients at risk of developing the disease at the above-described dosage levels, under the advice and supervision of a physician. Patients at risk of developing a particular disease usually include those with a family history of the disease or those identified as particularly susceptible to the disease through genetic testing or screening.
[0168] The compounds of the present invention may be administered as sole active agents, or they may be administered in combination with other therapeutic agents, including other compounds of the present invention, which exhibit the same or similar therapeutic activity and have been shown to be safe and effective in such combination administration. In specific embodiments, co-administration of two (or more) agents allows for the use of significantly lower doses of each agent, thereby reducing any observed side effects.
[0169] In one embodiment, the compound of the present invention or a pharmaceutical composition containing the compound of the present invention is administered as a pharmaceutical. In a specific embodiment, the pharmaceutical composition further contains additional active ingredients.
[0170] In one embodiment, the compounds of the present invention are co-administered with other therapeutic agents for the treatment and / or prevention of inflammatory diseases, and specific agents include, but are not limited to, immunomodulators such as azathioprine, corticosteroids (e.g., prednisolone or dexamethasone), cyclophosphamide, cyclosporine A, tacrolimus, mycophenolate mofetil, muromonab-CD3 (OKT3, e.g., orthoclone®), ATG, aspirin, acetaminophen, ibuprofen, naproxen, and piroxicam.
[0171] In one embodiment, the compounds of the present invention are co-administered with other therapeutic agents for the treatment and / or prevention of arthritis (e.g., rheumatoid arthritis), and specific agents include, but are not limited to, analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, synthetic DMARDs (e.g., methotrexate, leflunomide, sulfasalazine, auranofin, sodium aurothiomalate, penicillamine, chloroquine, hydroxychloroquine, azathioprine, tofacitinib, baricitinib, fostamatinib, and cyclosporine), and biological DMARDs (e.g., but are not limited to, infliximab, etanercept, adalimumab, rituximab, and abatacept).
[0172] In one embodiment, the compounds of the present invention are co-administered with another therapeutic agent for the treatment and / or prevention of proliferative disorders, and specific agents include, but are not limited to, methotrexate, leucovorin, adriamycin, prednisone, bleomycin, cyclophosphamide, 5-fluorouracil, paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine, doxorubicin, tamoxifen, toremifene, megestrol acetate, anastrozole, goserelin, anti-HER2 monoclonal antibodies (e.g., Herceptin®), capecitabine, raloxifene hydrochloride, EGFR inhibitors (e.g., Iressa®, Tarceva®, Elbitux®), VEGF inhibitors (e.g., Avastin®), proteasome inhibitors (e.g., Velcade®), Gleevec®, and hsp90 inhibitors (e.g., 17-AAG). Furthermore, the compounds of the present invention according to Formula I may be administered in combination with other therapies, including but not limited to radiotherapy or surgery. In specific embodiments, the proliferative disorder is selected from cancer, myeloproliferative disorders, or leukemia.
[0173] In one embodiment, the compounds of the present invention are co-administered with other therapeutic agents for the treatment and / or prevention of autoimmune diseases, and specific agents include, but are not limited to, glucocorticoids, cell proliferation inhibitors (e.g., purine analogs), alkylating agents (e.g., nitrogen mustard (cyclophosphamide), nitrosourea, the platinum compounds of the present invention, and others), antimetabolites (e.g., methotrexate, azathioprine, and mercaptopurine), cytotoxic antibiotics (e.g., dactinomycin, azathioprine, etc.). Examples include intracyclines (mitomycin C, bleomycin, and mitramycin), antibodies (e.g., anti-CD20, anti-CD25, or anti-CD3 (OTK3) monoclonal antibodies, Atogum® and Thymoglobulin®), cyclosporine, tacrolimus, rapamycin (sirolimus), interferon (e.g., IFN-β), TNF-binding proteins (e.g., infliximab, etanercept, or adalimumab), mycophenolates, fingolimod, and myriocin.
[0174] In one embodiment, the compound of the present invention is co-administered with another therapeutic agent for the treatment and / or prevention of transplant rejection, and specific agents include, but are not limited to, calcineurin inhibitors (e.g., cyclosporine or tacrolimus (FK506)), mTOR inhibitors (e.g., sirolimus, everolimus), antiproliferative agents (e.g., azathioprine, mycophenolic acid), corticosteroids (e.g., prednisolone, hydrocortisone), antibodies (e.g., monoclonal anti-IL-2Rα receptor antibodies, baziliximab, daclizumab), and polyclonal anti-T cell antibodies (e.g., anti-thymocyte globulin (ATG), anti-lymphocyte globulin (ALG)).
[0175] In one embodiment, the compound of the present invention is co-administered with another therapeutic agent for the treatment and / or prevention of asthma and / or rhinitis and / or COPD, and specific agents include, but are not limited to, β2-adrenergic receptor agonists (e.g., salbutamol, revalbuterol, terbutaline and bitolterol), epinephrine (inhalation or tablet form), anticholinergic agents (e.g., ipratropium bromide), glucocorticoids (oral or inhalation form), long-acting β2-agonists (e.g., salmeterol, formoterol, bambuterol and sustained-release oral albuterol), inhalation Examples include combinations of teroids and long-acting bronchodilators (e.g., fluticasone / salmeterol, budesonide / formoterol), leukotriene antagonists and synthesis inhibitors (e.g., montelukast, zafirlukast, and diloiton), mediator release inhibitors (e.g., cromoglycates and ketotifen), biomodulators of the IgE response (e.g., omalizumab), antihistamines (e.g., ceterizine, cinnarizine, fexofenadine), and vasoconstrictors (e.g., oxymetazoline, xylometazoline, naphazoline, and tramazoline).
[0176] Furthermore, the compounds of the present invention may be administered in combination with emergency treatment of asthma and / or COPD, such treatments include oxygen or heliox administration, salbutamol or terbutaline in spray form (optionally combined with anticholinergic agents (e.g., ipratropium)), systemic steroids (oral or intravenous, e.g., prednisone, prednisolone, methylprednisolone, dexamethasone, or hydrocortisone), intravenous salbutamol, nonspecific β-agonists, injectable or inhaled (e.g., epinephrine, isoethalin, isoproterenol, metaproterenol), anticholinergic agents (intravenous injection or spray, e.g., glycopyrrolate, atropine, ipratropium), methylxanthines (theophylline, aminophylline, vamiphylline), inhaled anesthetics having bronchodilating effects (e.g., isoflurane, halothane, enflurane), ketamine, and intravenous magnesium sulfate.
[0177] In one embodiment, the compounds of the present invention are co-administered with other therapeutic agents for the treatment and / or prevention of inflammatory bowel disease (IBD), including, but not limited to, glucocorticoids (e.g., prednisone, budesonide), synthetic disease-modifying immunomodulators (e.g., methotrexate, leflunomide, sulfasalazine, mesalazine, azathioprine, 6-mercaptopurine, and cyclosporine), and bio-disease-modifying immunomodulators (infliximab, adalimumab, rituximab, and abatacept).
[0178] In one embodiment, the compound of the present invention is co-administered with another therapeutic agent for the treatment and / or prevention of SLE, and specific agents include, but are not limited to, human monoclonal antibodies (belimumab (Benlysta)), disease-modifying antirheumatic drugs (DMARDs) such as antimalarial drugs (e.g., Plaquenil, hydroxychloroquine), immunosuppressants (e.g., methotrexate and azathioprine), immunosuppressants and analgesics such as cyclophosphamide and mycophenolic acid, nonsteroidal anti-inflammatory drugs, opioates (e.g., dextropropoxifen and cocodamole), opioids (e.g., hydrocodone, oxycodone, MS Contin, or methadone), and fentanyl duragesic transdermal patch.
[0179] In one embodiment, the compounds of the present invention are co-administered with other therapeutic agents for the treatment and / or prevention of psoriasis, and specific agents include, but are not limited to, topical therapeutic agents such as bath solutions, moisturizers, medicated creams and ointments containing coal tar, ditranol (antraline), corticosteroid-like desoximethasone (Topicort®), fluocinonide, vitamin D3 analogs (e.g., calcipotriol), argan oil, and retinoids (etretinate, acitretin, tazarotene); systemic therapeutic agents such as methotrexate, cyclosporine, retinoids, thioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, fumarate esters; or biologics such as Amevib®, Enbrel®, Humira®, Remicade®, Raptiva®, and ustekinumab (IL-12 and IL-23 blockers). Furthermore, the compounds of the present invention may be administered in combination with other therapies, including but not limited to phototherapy or photochemotherapy (e.g., psoralen and ultraviolet A therapy (PUVA)).
[0180] In one embodiment, the compound of the present invention is co-administered with another therapeutic agent for the treatment and / or prevention of allergic reactions, and specific agents include, but are not limited to, antihistamines (e.g., cetirizine, diphenhydramine, fexofenadine, levocetirizine), glucocorticoids (e.g., prednisone, betamethasone, beclomethasone, dexamethasone), epinephrine, theophylline, or anti-leukotriene agents (e.g., montelukast or zafirlukast), anticholinergics, and decongestants.
[0181] As will be apparent to those skilled in the art, co-administration encompasses all means of delivering two or more therapeutic agents to a patient as part of the same treatment regimen. These two or more agents may, but are not required, be administered simultaneously in a single formulation, i.e., as a single pharmaceutical composition. They may also be administered in different formulations and at different times. [Examples]
[0182] (Experiment Section) (General method) Powder X-ray diffraction data were collected using a PANalytical Empyrean diffractometer (PANalytical, Amlelo, Netherlands) equipped with an X'cellerator detector. The radiation used was CuKα (1.54A), and the voltage and current were set to 45kV and 40mA, respectively. Data were collected at room temperature with a step size of 0.013° 2θ from 3° to 40° 2θ. The sample was prepared between Mylar® films on a disc-shaped holder, and the diffraction profile was recorded in transmission mode while rotating the sample.
[0183] Differential scanning calorimetry (DSC) data were collected using a DSC Q1000 (or DSC Q2000) differential scanning calorimeter (TA Instruments, Newcastle, DE, USA). Data were collected over a temperature range of 25°C to 250°C at a heating rate of 10°C / min. Analysis was performed under nitrogen, and samples were packed into standard perforated aluminum dishes. Indium was used as the calibration standard.
[0184] Thermogravimetric analysis (TGA) data were collected using a TGA Q5000 thermogravimetric analyzer (TA Instruments, Newcastle, DE, USA). Data were collected over a temperature range of 25°C to 250°C at a heating rate of 10°C / min. Analysis was performed under nitrogen, and samples were packed into standard lidless aluminum dishes. Nickel was used as a temperature calibration standard using the Curie point method.
[0185] Infrared spectra were recorded using a Bruker ALPHA II infrared spectrophotometer (Bruker, Wissembourg, France). Data were recorded in ATR mode at 2 cm in the room temperature range. -1 The data was collected after averaging 24 scans at a resolution of [resolution value].
[0186] solid 13 The 13C NMR spectrum was obtained at ambient temperature using a Bruker SB Avance III HD 500 spectrometer with a 4mm CP / MAS SB VTN probe, as follows: -Frequency: 125.76MHz, - Spectral width: 37kHz, -Magic angle rotation speed: 10kHz, - Pulse program: Cross-polarization using SPINAL64 decoupling -Recycling delay: 10s, -Acquisition time: 46ms, -Contact time: 4ms, Total count: 4096 It was recorded under these conditions. Before the FT, 5 Hz line-broadening was applied. The resulting spectrum is shown for comparison with that of an adamantane sample (the high-frequency peak of adamantane was set to 38.5 ppm).
[0187] solid 15The N NMR spectrum was obtained at ambient temperature using a Bruker SB Avance III HD 500 spectrometer with a 4 mm CP / MAS SB VTN probe, as follows: -Frequency: 50.68MHz, - Spectral width: 25kHz, -Magic angle rotation speed: 5kHz, - Pulse program: Cross-polarization using SPINAL64 decoupling -Recycling delay: 30s, -Acquisition time: 40ms, -Contact time: 4ms, - Total count: 8192 It was recorded under these conditions.
[0188] Before the Fourier transform (FT), a 5 Hz linewidth expansion was applied. The resulting spectrum was then processed. 15 The results are shown for comparison and reference with a N-doped glycine sample (the frequency was set to 33.4 ppm within a reference frame corresponding to 0 ppm ± 0.2 ppm for ammonia, taking the interval between the two peaks of glycine).
[0189] Water sorption / desorption profiles were recorded using a Dynamic Vapor Sorption System (DVS) (Surface Measurement Systems, London, UK). Approximately 5–10 mg of the sample material was placed in the dish of the DVS instrument, operating at 25°C under controlled humidity. Mass fluctuations were recorded as a function of relative humidity according to the program detailed below: - The samples were equilibrated at 50% RH until the mass fluctuation was less than 0.002% per minute within a 6-hour time limit. - The relative humidity was increased from 50%RH to 90%RH at a rate of 10% per hour. - The samples were equilibrated at 90% RH until the mass fluctuation was less than 0.002% per minute within a 6-hour time limit. - The relative humidity was reduced from 90%RH to 0%RH at a rate of 10% per hour. - The samples were equilibrated at 0% RH until the mass fluctuation was less than 0.002% per minute within a 6-hour time limit. - The relative humidity was increased from 0%RH to 50%RH at a rate of 10% per hour. (abbreviation) [Table 1] TIFF2023552908000005.tif108170
[0190] (Example 1. Preparation by synthesis of the solid form of the present invention) (1.1. Preparation of amorphous (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazine-1-yl]-3-oxo-propyl]imidazolidined-2,4-dione) Amorphous material can be obtained by following the procedure for preparing compound 1 described in WO2016 / 102347, or by heating polymorph I to 100°C under vacuum.
[0191] The amorphous morphology was characterized by XRPD as shown in Figure 18.
[0192] The amorphous morphology was characterized by a DSC substantially as shown in Figure 20.
[0193] The amorphous morphology was characterized by thermogravimetric analysis (TGA) as substantially shown in Figure 19.
[0194] (1.2. Preparation of polymorph I of (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidined-2,4-dione) (1.2.1. Morphology I - Protocol 1) (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione and IPA (3.93 kg / kg MSM) are packed into the reactor at 20°C. The suspension is heated to 40°C to produce a solution, which is maintained at this temperature for 15 minutes. The solution is then clarified by filtration through a PALL filter.
[0195] The first load of water (5 kg / kg MSM) is added at 40°C for 30 minutes. This solution is cooled to 35°C in 15 minutes (gradient = -0.3°C / min), and then a seed crystal of crystalline (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazine-1-yl]-3-oxo-propyl]imidazolidin-2,4-dione is added. After 15 minutes, the suspension is cooled to 5°C in 100 minutes (gradient = -0.3°C / min).
[0196] The second load of water (2.5 kg / kg MSM) is added at 5°C over 15 minutes, and the medium is maintained at 5°C for at least 10 hours while stirring, before being filtered through a 20 μm filter.
[0197] Wash the cake twice with pre-cooled (5°C) water (2 × 2.50 kg / kg MSM). Dry the resulting solid in a ventilated oven at 40°C.
[0198] Polymorph I of (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione is obtained in 81% yield.
[0199] Polymorph I was characterized by XRPD (Figure 1).
[0200] Polymorph I is essentially characterized by a DSC as shown in Figure 3, exhibiting an endothermic transition at approximately 75-85°C (rise), and more specifically, when morph I is heated from approximately 25°C at a rate of 10°C / min in a perforated aluminum dish, it exhibits an endothermic transition at approximately 80°C.
[0201] Polymorph I was characterized by thermogravimetric analysis (TGA) as substantially shown in Figure 5, which revealed a weight loss in the range of approximately 8%. This weight loss was determined to be water by Karl Fischer (KF) analysis. The KF analysis indicates that the water content could be approximately 8%, corresponding to the dihydrate.
[0202] Polymorph I is located at the following positions: 3488.5, 1751.3, 1719.0, 1598.4, 1586.0, 1484.5, 1458.0, 1439.3, 1410.5, 1252.7, 1199.9, 1113.1, 1051.7, 1026.5, 992.2, 835.2, 807.5, and 675.7 cm. -1 It was characterized by infrared spectroscopy (IR), which is essentially shown in Figure 7, where a peak is observed.
[0203] Polymorph I is substantially shown in Figure 9, with peaks at the following positions: -3.7, -2.2, 1.2, 2.5, 8.7, 13.7, 14.3, 27.7, 29.2, 31.4, 31.8, 40.7, 42.2, 45.8, 46.3, 48.0, 50.4, 53.5, 64.1, 90.9, 91.7, 94.0, 96.6, 100.9, 152.4, 153.0, 159.1, 163.2, 164.1, 165.1, 166.1, 173.0, 174.8, and 178.8 ppm. 13 It was characterized by 13C solid-state NMR.
[0204] Polymorph I is substantially shown in Figure 11, with peaks at the following positions: 75.0, 76.8, 93.6, 94.9, 111.5, 115.1, 148.0, and 149.1 ppm. 15 It was characterized by N solid-state NMR.
[0205] (1.2.2. Morphology I - Protocol 2) Amorphous compound 1 (approximately 50 mg) was dissolved in acetone and stirred in a sealed glass vial for 30 minutes to obtain a clear solution. Then, water (0.5 mL to 1.5 mL) was added while stirring, and compound 1 precipitated as form I.
[0206] (1.3. Preparation of polymorph II of (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidined-2,4-dione) (1.3.1. Morphology II - Protocol 1) (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione and IPA (3.93 kg / kg MSM) are packed into the reactor at 20°C. The suspension is heated to 40°C to produce a solution, which is maintained at this temperature for 30 minutes. The solution is then clarified by filtration through a PALL filter, and crystalline (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione (0.01 kg / kg MSM) is added as a seed crystal.
[0207] After 15 minutes, the medium is cooled to 25°C in 150 minutes (gradient = -0.1°C / min), and maintained at this temperature for 60 minutes.
[0208] A methylcyclohexane load (8.18 kg / kg MSM) is added at 25°C over 90 minutes. The mixture is maintained at this temperature for 60 minutes, then cooled to 5°C over 200 minutes (gradient = -0.1°C / min), maintained at this temperature with stirring for 12 hours, and then filtered through a 20 μm filter.
[0209] The cake is washed with pre-cooled (5°C) MCH (2.40 kg / kg MSM). The resulting solid is dried under vacuum at 40-50°C.
[0210] Polymorph II of (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione is obtained in a yield of 65.6%.
[0211] Residual solvent: MCH (0.8%), IPA (<0.1%)
[0212] (1.4. Morphology II - Protocol 2) (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione and methyl isobutyl ketone (5 kg / kg MSM) are packed into the reactor at 20°C. The suspension is heated to 60°C to form a solution, which is maintained at this temperature for 15 minutes. The solution is then clarified by filtration through a PALL filter. The first load of DIPE (5 kg / kg MSM) is added at 60°C for 45 minutes. Next, a seed crystal of crystalline (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione (0.025 kg / kg MSM) is added to the solution. After 15 minutes, a further load of DIPE (5 kg / kg MSM) is added over 30 minutes. The medium is as follows: - Cooling to 50°C in 30 minutes (gradient = -0.3°C / min), contact time at 50°C for 60 minutes. - Cooling to 40°C in 30 minutes (gradient = -0.3°C / min), contact time at 40°C for 120 minutes. - Cooling to 30°C in 30 minutes (gradient = -0.3°C / min), contact time at 30°C for 120 minutes. - Cooling to 20°C in 30 minutes (gradient = -0.3°C / min), contact time at 20°C for 120 minutes. - Cool at 10°C in 30 minutes (gradient = -0.3°C / min), with a contact time of 120 minutes at 10°C, - Cool at 0°C in 30 minutes (gradient = -0.3°C / min), with a contact time of 120 minutes at 0°C Cool to 0°C.
[0213] Filter the medium through a 20 μm filter.
[0214] Wash the cake with pre-cooled (0°C) DIPE (5 kg / kg MSM). Dry the resulting solid under vacuum at 40 - 50°C.
[0215] Polymorphic form II was characterized by XRPD as shown in Figure 2.
[0216] Polymorphic form II was characterized by DSC as substantially shown in Figure 4, showing an endothermic transition at approximately 155 - 162°C (onset), and more specifically, when heating form II in a perforated aluminum dish, it showed an endothermic transition at approximately 159°C when heated from about 25°C at a rate of 10°C / min.
[0217] Polymorphic form II was characterized by thermogravimetric analysis (TGA) as substantially shown in Figure 6.
[0218] Polymorphic form II was characterized by infrared spectroscopy (IR) as substantially shown in Figure 7, showing peaks at the following positions: 1717.8, 1624.6, 1584.8, 1447.1, 1193.0, 1556.0, 1111.4, 1022.8, 987.4, 823.3, 765.1, and 672.7 cm -1 as shown in Figure 7.
[0219] Polymorph II is substantially as shown in Figure 9, showing peaks at the following positions: -0.9, 0.3, 2.1, 10.0, 12.3, 17.0, 29.1, 30.1, 34.4, 42.4, 45.7, 46.8, 49.1, 52.9, 65.6, 68.3, 91.7, 96.1, 97.5, 98.6, 102.3, 153.0, 153.9, 158.3, 163.6, 165.1, 170.0, 174.8, 180.9 ppm 13 was characterized by C solid NMR.
[0220] Polymorph II is substantially as shown in Figure 11, showing peaks at the following positions: 70.3, 80.4, 89.9, 97.4, 106.0, 108.9, 145.3, 146.5 ppm 15 was characterized by N solid NMR.
[0221] (1.4.1. Form II - Protocol 3) [Chemical formula] To a suspension of (4R)-4-methyl-2,5-dioxo-4-imidazolidinepropanoic acid (reference mass 1 wt, CAS 1957994-69-2) in methyl isobutyl ketone (7.8 wt / wt equivalent) at ambient temperature under nitrogen, the first batch of N,N-DIPEA (0.6 wt / wt equivalent) was added over 60 minutes with stirring, followed by the second batch of N,N-DIPEA (1.5 wt / wt equivalent) added over 60 minutes.
[0222] Next, (2S)-1-(3,5-difluorophenyl)-2-methylpiperazine (2.0 wt / wt equivalent, CAS 845740-76-3) was added over about 70 minutes while maintaining the temperature at 20 - 25 °C, followed by propane phosphonic anhydride (50%) in methyl THF (3.6 wt / wt equivalent) added over about 2.5 hours while maintaining the temperature in the range of 20 - 25 °C.
[0223] The reaction mixture was kept at 20-25°C for 45 minutes with stirring, then the batch temperature was raised to 38-42°C over 1 hour, maintained for 2 hours and 15 minutes, and then cooled to 20-30°C.
[0224] Purified water (4.9 wt / wt equivalent) was added to the reaction mixture over 70 minutes while maintaining the temperature in the range of 20-30°C, and the mixture was kept at that temperature for another 15 minutes with stirring. The stirring was stopped, and the phases were separated. To the organic layer, a solution of 32% hydrochloric acid (0.3 wt / wt equivalent) in purified water (4.9 wt / wt equivalent) was added over 30 minutes while maintaining the temperature at 20-25°C during batch addition.
[0225] The batch was continuously stirred, then the stirring device was stopped, the phases were separated, a 5 wt% aqueous solution of ammonium chloride (4.9 wt / wt equivalent) was added, and the batch was stirred at 20-25°C. Then the stirring device was stopped, and the phases were separated. A 5 wt% aqueous solution of ammonium chloride (4.9 wt / wt equivalent) was added again, and the batch was stirred at 20-25°C. Then the stirring device was stopped, and the phases were separated. The organic phase was washed again with purified water (4.9 wt / wt equivalent), the organic phase was separated, and the mixture was distilled, first at atmospheric pressure and then under vacuum, until the internal temperature reached a value higher than 101°C.
[0226] Next, the residue was diluted in methyl isobutyl ketone (1.4 wt / wt equivalent), heated to approximately 60°C for about 17 minutes, and then cooled to 20-25°C. The batch was filtered through a 0.5 μm cartridge, and the cartridge was rinsed with methyl isobutyl ketone (1.4 wt / wt equivalent).
[0227] The obtained solution was heated to 58-62°C, and diisopropyl ether (11.7 wt / wt equivalent) was added over 25 minutes while maintaining the batch at 58-62°C. Seed crystals were added to the solution, and diisopropyl ether was added three more times (2.6 wt / wt equivalent, 2.6 wt / wt equivalent, and 8.9 wt / wt equivalent). The resulting suspension was then cooled to 0-5°C over 14 hours. The resulting suspension was left at that temperature for about 2 hours, and then the solid was separated by centrifugation, washed with pre-cooled diisopropyl ether (8.9 wt / wt equivalent), and dried at 48°C for 20 hours to obtain the title compound.
[0228] (1.4.2. Morphology II - Protocol 4) Amorphous compound 1 (approximately 50 mg) was dissolved in methanol or ethanol and stirred in a sealed glass vial for 30 minutes to obtain a clear solution. Then, water (0.5 mL to 1.5 mL) was added while stirring to precipitate compound 1 as form II.
[0229] (1.4.3. Morphology II - Protocol 5) Amorphous compound 1 (498 mg) and 5 mL of MTBE were stirred until a clear solution was obtained, then stirred for a further 3 hours to precipitate compound 1 as form II, which was separated by filtration and finally dried.
[0230] (1.5. Preparation of polymorph III of (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidined-2,4-dione) Amorphous material (200 mg) is slurryed in MTBE (400 μL) at room temperature. To accelerate the crystallization of Form 3, a seed crystal of Form 3 may be added to the mixture after stirring for 2 hours. After 3 days, the solid is dried at free air and analyzed by XPRD, TGA, and DSC.
[0231] Polymorphic form III was characterized by an XRPD as shown in Figure 15.
[0232] Polymorphic form III showed a transition at approximately 111 - 170 °C (onset), and more specifically showed a transition to form III at approximately 140 °C when heated from about 25 °C at a rate of 10 °C / min in a perforated aluminum dish, as substantially shown in FIG. 16, and was characterized by DSC.
[0233] Polymorphic form III was characterized by thermogravimetric analysis (TGA) as substantially shown in FIG. 17.
[0234] (Example 2. Stability Test of the Solid Forms of the Present Invention) The stabilities of the solid forms of Compound 1 as amorphous, form I, and form II were evaluated under various conditions. It is reported below. All three forms were shown to be stable.
Table 2
[0235] (Biological Data) (Example 3. Pharmaceutical Composition) (3.1. PK Test in Humans) After a single oral administration of 300 mg of Compound 1 to healthy male subjects (18 subjects per group) as 30% or 50% drug content tablets of crystalline form I and crystalline form II under fasting conditions and / or fed conditions, the concentration of Compound 1 in human plasma was determined by liquid chromatography using protein precipitation extraction and tandem mass spectrometry (LC - MS / MS) detection.
[0236] The lower limit of quantification was 1 ng / mL. In each analysis, two replicates of QC samples were analyzed along with the test samples.
[0237] At various points in time, blood samples (2 mL) for determining compound 1 in plasma were collected in tubes containing lithium heparin and immediately cooled (ice bath). Within 30 minutes of blood collection, the plasma was separated in a cooled centrifuge at 4°C for 10 minutes to approximately 1,500 g.
[0238] Pre-administration PK samples were collected within 15 minutes prior to administration, and then at the following time points: 0.5 hours, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours, 16 hours, 24 hours, 48 hours, and 72 hours. A ±5 minute window was allowed for all PK samples between 0.5 hours and 16 hours; a ±30 minute window was allowed for samples between 24 hours and 72 hours.
[0239] All statistical analyses were performed using SAS® version 9.4 (or later) (SAS Institute, Cary, NC, USA) and / or Phoenix WinNonLin (version 8 or later) software.
[0240] All relevant data was documented using summary tables, figures, and target data lists.
[0241] The summary tables show, for continuous variables, the number of non-missing observations, the arithmetic mean, the standard deviation (SD) and / or standard error (where applicable), the median, minimum, and maximum values, as well as the number and percentage for each category for categorical data. For PK data, the number of data points exceeding the lower limit of quantification (applicable only to concentration), the coefficient of variation (CV%), the geometric mean, and the geometric CV% are also shown. In addition to the descriptive statistics summarized in the tables, the data was also presented using graphs. Unless otherwise specified, inferential statistics were interpreted at a two-sided 5% significance level. (Table I. PK measurement parameters for morphology I and morphology II) [Table 3]
[0242] When tested using this protocol, there was no difference in median tmax for any of the tablets, but an increase in plasma peak exposure (Cmax) was observed in polymorph II compared to polymorph I (34% and 40% for 30% and 50% content tablets, respectively, under fasting conditions).
[0243] (Example 4. In vivo model) (4.1. Protein overload model, Nephrectomy model) This animal model allows for the evaluation of the efficacy of the compounds of the present invention in kidney diseases, including renal fibrosis.
[0244] (4.1.1. Materials) This study was conducted using Balb / c mice (Charles River).
[0245] All mice were housed under standardized conditions of a 12-hour day / 12-hour night light cycle, fed standard solid feed ("https: / / insights.envigo.com / hubfs / resources / data-sheets / 2018-datasheet-0915.pdf"), and had free access to water.
[0246] The animals were allowed to acclimate for at least a week before the procedure began.
[0247] In mice, a unilateral left-sided nephrectomy was performed via a short lateral incision under anesthesia.
[0248] Siamese control mice underwent only incisions. The mice were allowed to recover from surgery for 7 days.
[0249] (4.1.2. Experimental Protocol) Drug treatment was started one day before the protein overload was initiated.
[0250] Each mouse was administered by forced oral administration either 240 mg / kg / day of compound 1 or 10 mg / kg / day of lisinopril (lisinopril once plus vehicle once) or vehicle alone (0.5% methylcellulose containing 2% Tween 80 - twice daily) at 8:00 and 15:30 each day.
[0251] Siamese mice were given vehicle alone. Protein overload was initiated by daily intraperitoneal injections of 450 mg / ml BSA solution (Sigma catalog A4919: low endotoxin) in sterile filtered saline for 14 days, starting at 2 mg / g body weight on day 1 and increasing to 15 mg / g on day 7, according to the following schedule: (Table II. Medication schedule for protein overload model and nephrectomy model) [Table 4]
[0252] Siamese mice were given an equal volume of saline solution. After the final injection, the mice were placed in metabolic cages for 24 hours of urine collection.
[0253] Next, the mice were anesthetized and then sacrificed. Blood samples were collected. The remaining right kidney was perfused with PBS (Sigma 806552) + 10mM EDTA (Invitrogen 15575-02-Stock 0.5M), then excised and dissected laterally.
[0254] Half of the spleen was placed in formalin in preparation for paraffin blocking for use in immunohistochemistry, and the other half was lightly tapped and dried, then placed in liquid nitrogen for later proteomics analysis. The spleen was also removed and cut in half for FFPE and proteomics.
[0255] (4.1.3. Statistical analysis method) All data were expressed as mean ± SEM. Results were analyzed using GraphPad Prism 8. For datasets >8, D'Agostino-Pearson omnibus normality tests were performed to assess normality, and the Shapiro-Wilk test was performed for datasets <8. For multiple comparisons, one-way ANOVA with Tukey's post-hoc correction (parametric) or Kruskal-Wallis test with Dunn's post-hoc test (non-parametric data) was used. ELISA standard curves were plotted using a sigmoid 4PL fit where x is the logarithm of standard concentrations. Relative mRNA expression levels were calculated using the Livak equation as 2-ΔCt. A confidence interval of 0.95, p ≤ 0.05, was applied to all statistical tests.
[0256] The following evaluation criteria: -Urine protein concentration mg / mL -Urinary protein / mg creatinine (mg / mg) - Serum protein concentration (mg / mL) - Urinary creatinine concentration (mg / dL) (mg / mL) - Serum creatinine concentration (mg / dL) -Serum urea concentration (mg / dL) - Versikine, NITEGE, ARGS dot blot - Immunohistochemistry: ADAMTS5, collagen I, collagen IV, fibronectin, CD45, complement C3, F4 / 80 We measured it. (4.1.4. Results) Following the protocol described above, the following values were measured on day 14 (see Figure 21). As shown in the table below, compound 1 showed a statistically significant improvement in proteinuria compared to the vehicle group (p<0.05, *): (Table III. Proteinuria in individual subjects - Figure 21) [Table 5] TIFF2023552908000011.tif80170 (Table IV. Statistical Analysis: Proteinuria - Figure 21) [Table 6]
[0257] (4.2. Duchenne muscular dystrophy MDX model) (4.2.1. Background) Male mdx mice are the most widely used animal model in preclinical Duchenne muscular dystrophy (DMD) research (McGreevy et al., 2015).
[0258] (4.2.2. Protocol Overview) Five-week-old mdx mice (Animal Resource Centre; Perth, WA, Australia) were acclimatized to their environment for one week, and then randomly assigned to one of four treatment groups or a control group (15 animals per group) as shown in the table below. At the start of the study, these groups were matched in terms of mouse body weight. (Table V. Mdx Model Group Allocation) [Table 7]
[0259] After one week of acclimatization, i.e., at approximately 6 weeks of age, the following baseline measurements were performed: -Grip strength according to the standard operating procedures for preclinical Duchenne muscular dystrophy research as described in the TREAT-NMD guidelines ("https: / / treat-nmd.org / wp-content / uploads / 2016 / 08 / MDX-DMD_M.2.2.001.pdf" nd) -Body composition analysis using an EchoMRI scanner Spontaneous physical activity and systemic metabolism were determined for all treated mice (compound 1, prednisolone, compound 1 + prednisolone, or vehicle) using a Promethion system that records respiratory gases (O2 and CO2).
[0260] These measurements were repeated during treatment (approximately 10 weeks of age, i.e., at 4 weeks of treatment) and at the end of the study (approximately 15 weeks of age, i.e., at 9 weeks of treatment) to evaluate the effects of compound 1, prednisolone, or compound 1 + prednisolone on dystrophy pathology in MDX mice, to assess the long-term functional evaluation of muscle pathology in MDX mice, and to determine whether drug treatment alters the trajectory of these physiological markers of dystrophy muscle pathology.
[0261] Untreated control mdx mice were restrained from the beginning to the end of the study. After a one-week acclimatization period, these mice also underwent baseline measurements of grip strength and body composition. This was repeated at approximately 10 weeks and 15 weeks of age. In addition, these mice were periodically weighed, and urine was collected at approximately 6 weeks, 10 weeks, and 15 weeks of age.
[0262] At approximately 11–13 weeks of age (and 5–7 weeks after treatment), 200 μL of blood was collected from mdx mice treated with compound 1 or compound 1 plus prednisolone for pharmacokinetic analysis of the serum concentration of compound 1.
[0263] At this point, blood samples were collected for each of the two treatment groups (compound 1 and compound 1 + prednisolone) at the following time points: - 0 hours (before administration, N=4 mice) - 0.25 hours after administration (N = 4 mice) - 2 hours after administration (N = 4 mice) - 6 hours after administration (N = 3 mice) It was collected there.
[0264] To evaluate the effects of compound 1 or compound 1 + prednisolone on ECM remodeling (e.g., protein cleavage of ADAMTS-5 ECM protein substrates such as versican (Stupka et al., 2013)), urine was collected three times at approximately 6 weeks, 10 weeks, and 15 weeks of age, i.e., before, during, and after treatment, for analysis of matricine (degradation fragments of extracellular matrix proteins).
[0265] After 9 weeks of treatment, MDX mice (n=3-4 mice per day) were tested for contractile function (hindlimb (anterior tibia) and diaphragm muscles). The mice were treated at different times each week, with the treatment starting at a later date (n=3-4 mice per treatment group).
[0266] (4.2.3. Contraction function test) The procedure for testing the contraction function of the anterior tibial and diaphragmatic muscles is described below. A standard procedure for testing contraction function existed.
[0267] To evaluate the contractile function of the tibialis anterior muscle in situ, mice were anesthetized and the distal portion of the tibialis anterior (TA) muscle and its tendon were exposed.
[0268] The tendons were tied with top and bottom knots using needle-and-suture threads, then the distal tendons were severed, and the distal portion of the TA muscle was cut to free it from the surrounding tissue. The sciatic nerve was exposed above the knee joint. The mouse was then fixed proximal to a heated platform of a contraction function device. The distal end of the TA was securely tied to a lever arm attached to an isometric force transducer connected to a computer that recorded the output. Throughout the contraction function test protocol, warmed saline solution was applied to the exposed muscle and nerve tissue. Electrical pulses were applied to the sciatic nerve to induce TA muscle contraction, and this contraction was measured and recorded by the force transducer.
[0269] Finally, the mice were sacrificed after the in situ contraction function test. The left and right TA muscles, extensor digitorum longus (EDL), soleus muscle, and quadriceps muscle were collected for histological, immunohistochemical, and biochemical analysis.
[0270] Blood samples were also collected to evaluate biomarkers for dystrophy muscle pathology.
[0271] Additionally, the diaphragm and heart were collected, and the diaphragm was placed in an organ cisternum bubbling with carbogen, 5% CO2, and 95% O2 for ex vivo contraction function testing.
[0272] Finally, long bones (femur and tibia) and vertebrae were also collected for further analysis.
[0273] (4.2.4. Biomarkers) Matricaine levels were measured in urine collected before, during, and after the procedure.
[0274] Plasma samples were also analyzed.
[0275] RNA-seq and muscle gene expression were evaluated in diaphragm and TA muscle samples collected using RNA-later.
[0276] (4.2.5. Skeletal muscle) Muscle fiber size and the percentage of central nucleus muscle fibers (markers of damage and regeneration) were also analyzed, including laminin (basement membrane marker) immunohistochemistry and quantitative imaging analysis.
[0277] Muscle progenitor cells and newly regenerated muscle fibers were also evaluated by desmin immunohistochemistry and quantitative image analysis.
[0278] Inflammatory markers such as CD68 (a monocyte and panmacrophage marker) were evaluated by immunohistochemistry and quantitative imaging analysis.
[0279] Fibrosis markers were analyzed using Sirius Red for collagen, fluorescein isothiocyanate-wheat germ lectin (FITC-WGA) for ECM complex carbohydrates, and quantitative imaging analysis and histological examination using a hydroxyproline assay for collagen content.
[0280] Intramuscular adipocytes were manually counted on hematoxylin and eosin (H&E) stained muscle sections as an initial assessment.
[0281] (4.2.6. Bones) Bone strength was evaluated by three-point flexion of the tibia.
[0282] The bone structure was evaluated by microctimetric CT analysis of the cortical and trabecular bone of the femur.
[0283] The structure of the epiphyseal plate was evaluated by hematoxylin and eosin (H&E) staining (femur) and quantitative image analysis. GC treatment has adverse effects on the epiphyseal plate.
[0284] Morphometric measurements of femoral tissue were performed on bone marrow adipose tissue (von Kossa), osteoblasts (ALP), and osteoclasts (TRAP).
[0285] The vertebral structure was evaluated using μCT analysis.
[0286] (4.2.7. Results) When the above protocol was implemented, compound 1 showed a statistically significant improvement in grip strength compared to the control group (Figure 22).
[0287] Furthermore, in contrast to the prednisolone treatment group, which is the standard treatment for Duchenne dystrophy associated with bone loss (Novotny et al., 2012), statistically significant maintenance of bone and tissue volume was observed (Figure 23). (Table VI. Grip strength results - Figure 22 (Vehicle (black circle), Compound 1 (black square), Prednisolone (upward-pointing black triangle), and Compound 1 + Prednisolone (downward-pointing black triangle)) [Table 8] Av g / g BW: Average power output per gram of body weight SD: standard deviation SEM: Standard error of the mean (Table VII. Measurement of bone loss - Figure 23) [Table 9]
[0288] (4.3. Rat CDHFD model) (4.3.1. Overview) The choline-deficient L-amino acid-limited high-fat diet model (CDHFD) is a model that develops fatty liver disease, hepatic fibrosis, and liver cancer formation similar to that of the MCD diet (Santhekadur et al., 2017), and can be used to evaluate the compounds of the present invention.
[0289] (4.3.2. Animals) At introduction, 8-week-old male Wistar Han rats (Charles River, France) were housed at 22°C ± 2°C and 55% ± 10% humidity using a 12-hour dark / light cycle. They were fed either a standard solid diet (A124550KR, Research Diet, USA) or a high-fat (45% kCal fat) choline-deficient (CDHF) diet (A16092003, Research Diet, USA) containing 0.1% methionine and 1% cholesterol for 12 weeks. All animals had access to filtered drinking tap water.
[0290] (4.3.3. Examination) Six weeks after introduction, the animals were assigned to either the control group or the test group. To ensure homogeneity, rats were randomly assigned to the treatment group based on their body weight, serum bilirubin, and transaminase levels. Test group animals were administered 50 mg / kg of the test compound orally twice daily in 0.5% methylcellulose. The control group was given a similar volume of vehicle (10 mL / kg), i.e., standard feed for control group 1 (C1), CDHF feed for control group 2 (C2, 12 weeks), and a positive control formulated in CDHF feed + 0.5% methylcellulose + 98.9% water (compound C, 12 weeks).
[0291] After slaughter (week 12), the activity of the test compound against the development of NASH was evaluated by plasma alanine aminotransferase (ALT), serum alkaline phosphatase (ALP), and aspartate aminotransferase (AST) levels, as well as by quantitative analysis of improved liver fibrosis (ELF) biomarkers. In the liver, the activity was evaluated by histopathological examination of fibrosis and fatty liver (Sirius Red, Oil Red O), lipid levels (triglycerides, non-esterified fatty acids (NEFA), cholesterol) content, and the expression of fibrotic and inflammatory genes.
[0292] (4.3.4. Results) When this protocol was implemented, the test compound administered orally at 50 mg / kg twice daily in 0.5% methylcellulose showed statistically significant reductions in serum AST (-27%), α2 macroglobulin (-63%), procollagen (-48%), and hyaluronan (-65%) levels compared to the vehicle group. In the liver, the test compound showed a statistically significant reduction in liver fibrosis (-48%).
[0293] (4.4. Graft-versus-host (cGvhD) lung model) (4.4.1. Overview) In this cGvHD model, fibrosis is defined as B10.D2(H2 d) Allogeneic transplantation of bone marrow cells and splenocytes derived from donor mice (minor HLA mismatch) leads to BALB / c(H2 d The drug was induced in mice. The recipient mice developed inflammation-driven skin and pulmonary fibrosis similar to that seen in patients with rapidly progressive diffuse systemic sclerosis cutaneously (Zerr et al., 2012).
[0294] Treatment was performed only after the onset of the initial clinical symptoms of scleroderma-associated cGvHD.
[0295] (4.4.2. Test Group) The following groups, each containing eight mice, were used in this study. - Syngeneic transplant placebo-treated control group: Syngeneic bone marrow and splenocyte transplantation (BALB / c(H2 d )→BALB / c(H2 d )) 0.5% methylcellulose was administered from day 21 to day 56 post-transplant. - Vehicle-treated fibrosis group: Allogeneic bone marrow and splenocyte transplantation (B10.D2(H2) d )→BALB / c(H2 d )) 0.5% methylcellulose was administered from day 21 to day 56 post-transplant. - A control group to evaluate the pre-treatment level of fibrosis induced by allograft: Allogeneic bone marrow and splenocyte transplantation (B10.D2(H2) d )→BALB / c(H2 d )). After slaughtering on the 21st, processing began in other groups. - Treatment group: Allogeneic bone marrow and splenocyte transplantation (B10.D2(H2) d )→BALB / c(H2 d )) . Administration of the test compound of the present invention from day 21 to day 56 post-transplant. - Positive control group: Allogeneic bone marrow and splenocyte transplantation (B10.D2(H2) d )→BALB / c(H2 d Nintedanib was administered once daily at a dose of 50 mg / kg from day 21 to day 56 post-transplant.
[0296] (4.4.3. Steady-state PK) For the group administered the test compound on D20, blood was collected from the tail veins of two animals at each of the following time points: before administration, 1, 3, and 6 hours after administration, using the anticoagulant Li-heparin.
[0297] Blood samples were stored on ice and centrifuged at approximately 3500 × g for 10 minutes at +4°C within one hour of collection; the plasma was transferred to polypropylene tubes and stored at -20°C.
[0298] (4.4.4. Sampling and Analysis) The animals were euthanized two hours after the final dose, and samples of skin (3mm punch biopsy), lungs, spleen, and blood were collected for histological examination and gene expression analysis.
[0299] (4.4.5. Main Readouts) The antifibrotic effects on the skin were analyzed by determining skin thickness, quantifying damaged collagen, and staining myofibroblasts.
[0300] In cases where a positive effect was observed against dermatofibrosis, the effect on pulmonary fibrosis was analyzed by Ashcroft scoring, hydroxyproline content, and quantification of collagen coverage area using Sirius Red staining.
[0301] (4.4.6. Analysis) Based on the raw data of individual animals, the mean was determined for each group, and the percentage change from the disease control was calculated. The treatment groups were compared to the disease control using one-way ANOVA with Dunnett's post-hoc analysis for measured (parametric) data, or the Kruskal-Wallis test with Dunn's post-hoc analysis for scored (nonparametric) data.
[0302] (4.4.7. Results) When this protocol was implemented, compound 1 administered orally at 120 mg / kg twice daily in Tween 80 / methylcellulose 0.5% (2 / 98) showed a statistically insignificant decrease in skin thickness, but a statistically significant decrease in myofibroblast count (-35%) and hydroxyproline content in the skin (-8.3%).
[0303] In the lungs, compound 1 showed a statistically significant decrease in Ashcroft score (-1.3 times) and a decrease in collagen-covered lung area (-1.2 times) compared to the vehicle group.
[0304] (Conclusion) Those skilled in the art will understand that the foregoing description is illustrative and descriptive in nature and intended to illustrate the present invention and its preferred embodiments. Through routine experimentation, those skilled in the art will recognize obvious modifications and changes that can be made without departing from the spirit of the invention. All such modifications that fall within the scope of the appended claims are intended to be included therein. Accordingly, the present invention is intended to be defined not only by the foregoing description but also by the following claims and their equivalents. (References) [Table 10] TIFF2023552908000017.tif246170TIFF2023552908000018.tif63170
Claims
1. Formula I: 【Chemistry 1】 A solid form of a compound according to the formula (I) or a pharmaceutically acceptable solvate thereof.
2. 10. The solid form of claim 1, characterized by a powder X-ray diffraction pattern using Cu Kα radiation comprising peaks at 6.2, 12.5, 15.7, 19.1, 25.2, 26.4±0.2 degrees 2θ.
3. 10. The solid form of claim 1, characterized by a powder X-ray diffraction pattern using Cu Kα radiation comprising peaks at 6.2, 12.5, 14.1, 15.7, 19.1, 21.4, 22.4, 25.2, 26.4±0.2 degrees 2θ.
4. 10. The solid form of claim 1, characterized by a powder X-ray diffraction pattern using Cu Kα radiation comprising peaks at 6.2, 12.5, 14.1, 14.6, 15.6, 15.7, 17.8, 18.0, 18.8, 19.1, 19.7, 20.8, 21.4, 22.4, 25.2, 26.4, 28.9, 29.0±0.2 degrees 2θ.
5. 4. The solid form of any one of claims 1 to 3, having an X-ray powder diffraction profile substantially as shown in Figure 1.
6. 6. The solid form of any one of claims 1 to 5, having an endothermic transition at about 80°C as measured by differential scanning calorimetry.
7. 10. The solid form of claim 1, characterized by a powder X-ray diffraction pattern using Cu Kα radiation comprising peaks at 10.3, 15.3, 15.7, 16.7, 18.6±0.2 degrees 2θ.
8. 8. The solid form of claim 7, further characterized by a powder X-ray diffraction pattern using Cu Kα radiation comprising peaks at 16.7, 24.5, 30.4±0.2 degrees 2θ.
9. 9. The solid form of claim 7 or 8, further characterized by a powder X-ray diffraction pattern using Cu Kα radiation comprising peaks at 8.5, 12.6, 13.2, 13.6, 14.7, 18.3, 20.3, 20.8, 22.9, 27.2±0.2 degrees 2θ.
10. 10. The solid form of any one of claims 1 and 7 to 9, having an X-ray powder diffraction pattern substantially as shown in Figure 2.
11. 11. The solid form of any one of claims 1 and 7-10, having an endothermic transition at about 159°C as measured by differential scanning calorimetry.
12. A process for the preparation of the solid form of any one of claims 2 to 6, comprising: a) combining amorphous (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione and isopropyl alcohol; b) heating the mixture to about 40°C; c) adding a first batch of water; d) cooling the mixture to about 5°C at a rate of about 0.3°C / min; e) adding a second batch of water; f) filtering the mixture; g) washing the cake with chilled water; h) Drying the solid The method comprising:
13. A method for the preparation of a solid form according to any one of claims 7 to 11, comprising: a) combining amorphous (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione and isopropyl alcohol; b) heating the mixture to about 40°C; c) cooling the mixture to about 25°C at a rate of about 0.1°C / min; d) adding methylcyclohexane; e) cooling the mixture to about 5°C at a rate of about 0.1°C / min; f) filtering the mixture; g) washing the cake with chilled methylyl cyclohexane; h) Drying the solid The method comprising:
14. A method for the preparation of a solid form according to any one of claims 7 to 11, comprising: a) combining amorphous (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione and methyl isobutyl ketone; b) heating the reaction to about 60°C; c) adding diisopropyl ether; d) cooling the mixture to about 0°C in 10°C increments at a rate of about 0.3°C / min with a contact time of at least 60 minutes between each step; e) filtering the mixture; f) washing the cake with chilled diisopropyl ether; g) Drying the solid The method comprising:
15. 12. A pharmaceutical composition comprising the compound of any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
16. 16. A compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 15, for use in the treatment of the prevention and / or treatment of inflammatory conditions, muscle disorders, fibrotic disorders, viral infections, and / or diseases involving cartilage degradation and / or disturbance of cartilage homeostasis.
